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Abstract

DISCRIMINATIVE STIMULUS PROPERTIES OF 3-SUBSTITUENT RIMONABANT
ANALOGS
By David Matthew Walentiny, M.S.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2011
Major Director: Jenny L. Wiley, Ph.D.
Professor
Department of Pharmacology & Toxicology
Cannabinoid agonists (e.g., THC) dose-dependently decrease locomotor activity and
body temperature and produce antinociception and catalepsy. Drugs that produce this tetrad of
effects within a limited dose range are likely to function as CB1 receptor agonists. A structure
activity relationship study from our laboratory investigating analogs of the CB1 antagonist
rimonabant revealed that certain alterations in the 3-substituent of rimonabant’s pyrazole core
conferred agonist-like properties in the tetrad. Interestingly, these effects were present in CB1 -/mice, and were not reversed by rimonabant in wild-type mice. The present study evaluated two
novel 3-substituent rimonabant analogs, O-6629 and O-6658 in the tetrad and drug
discrimination, a preclinical model of drug subjective effects that possesses a high degree of
pharmacological specificity. Drugs that elicit cannabinergic psychoactive effects in humans are

likely to produce THC-like operant responding in animals trained to discriminate between the
interoceptive stimuli produced by THC relative to vehicle.
O-6629 and O-6658 decreased locomotor activity and body temperature and produced
catalepsy. O-6629, but not O-6658 produced significant antinociception. However, these drugs
differed from THC in regard to the magnitude of tetrad effects observed. These analogs also
failed to elicit THC-like discriminative stimulus effects, nor did they antagonize THC’s
discriminative stimulus in mice discriminating 5.6 mg/kg THC from vehicle. Finally, mice were
trained to discriminate 5.6 mg/kg O-6629 from vehicle. O-6658 produced full substitution for O6629, whereas the cannabinoid agonists THC and anandamide did not. O-6629’s discriminative
stimulus failed to generalize to rimonabant, cocaine or morphine, whereas WIN 55,212-2 and
nicotine evoked partial substitution. These results suggest that these analogs might exert their
pharmacological properties through a novel cannabinoid receptor, as has been proposed for WIN
55,212-2 and anandamide. Additionally, O-6629’s discriminative stimulus may involve nicotinic
acetylcholine or dopaminergic components. Future directions include determining whether the
partial substitution observed with nicotine was mediated through a nicotinic mechanism. Tests
with chlorpromazine, an antipsychotic that is a false positive in the tetrad, and diazepam, which
produces partial substitution for THC’s discriminative stimulus through a GABAergic
mechanism are also planned.

Discriminative stimulus properties of 3-substituent rimonabant analogs
Cannabinoid pharmacology
The endogenous cannabinoid (hereto referred as endocannabinoid) system is comprised
of two primary G-protein coupled receptors, cannabinoid 1 (CB1) and cannabinoid 2 (CB2), and
two major endogenous ligands, anandamide and 2-arachidonoylglycerol (2-AG), which activate
these receptors. CB1 receptors are located primarily in the brain whereas CB2 receptors are
located abundantly in the periphery suggesting functionally different roles for these receptors.
Two decades of research have revealed much regarding anandamide’s role within the
endocannabinoid system. Strong evidence suggests that membrane bound arachidonic acid is
likely the precursor for anandamide formation though its synthesis has yet to be completely
mapped or understood. Identification of anandamide’s degradative pathway has revealed that
fatty acid amide hydrolase (FAAH) is primarily responsible for the rapid catabolism of
anandamide (Cravatt et al., 1996). Similarly, 2-AG is quickly degraded by a number of enzymes,
with monoacylglycrol lipase (MAGL) serving as the primary catabolic enzyme (Long et al.,
2009). Development of more stable endocannabinoid ligand analogs (e.g., methanandamide),
selective inhibitors of FAAH and/or MAGL (e.g., URB597, JZL184, JZL195), and the
development of various cannabinoid-related knockout mice (e.g., CB1 -/-, CB2 -/-, FAAH

-/-,

MAGL -/-) have facilitated further understanding of the endocannabinoid system and
consequently have yielded valuable information regarding its impact on a multitude of biological
processes. Accordingly, the endocannabinoid system has become a target of interest for a
number of therapeutic purposes, such as management of pain, nausea and emesis. However, the
abuse liability and intoxication associated with cannabis greatly limits its accepted therapeutic

1

use. The following is a brief review of preclinical literature demonstrating the reinforcing
efficacy and intoxicating properties of cannabinoids.
Reinforcing properties of cannabinoids
The reinforcing properties of cannabinoids have been especially challenging to
demonstrate reliably in a preclinical setting. There have been numerous reports that Δ9tetrahydrocannabinol (THC), the primary psychoactive chemical in marijuana (Gaoni &
Mechoulam, 1964), fails to maintain self-administration behavior (Kaymakcalan, 1973; Leite &
Carlini, 1974; Carney, Uwaydah, & Balster, 1977; Mansbach, Nicholson, Martin, & Balster,
1994), a preclinical model used to examine reinforcing efficacy of drugs (Balster, 1991).
However, Tanda et al. (2000) demonstrated that THC does indeed maintain self-administration
using a lower dose range per infusion than had typically been studied. In that study, squirrel
monkeys with prior experience self-administering cocaine ( as reported by Spear, Muntaner,
Goldberg, & Katz, 1991) were given a 5 day saline replacement following their most recent
cocaine exposure, during which operant responding for an infusion was nearly abolished.
Following this extinction period, subjects then were able to respond for 2-4 µg/kg/infusion THC.
This low dose infusion, described as comparable to the THC amount inhaled by a human per
puff on a marijuana cigarette, readily maintained operant responding. Further, these effects were
reversed by pretreatment with selective CB1 antagonist/inverse agonist rimonabant (0.3 mg/kg),
whereas responding for cocaine was not influenced by rimonabant, demonstrating CB1
mediation of the reinforcing properties of THC. Once rimonabant pretreatment was ceased,
THC-maintained operant responding was reestablished and returned to baseline levels. Although
rates of responding for THC and cocaine infusions were comparable, this does not necessarily
imply that THC possesses the same degree of reinforcing efficacy as cocaine. A multitude of
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procedural parameters, including dose, reinforcement schedule (e.g., FI, FR, second-order) and
exposure (e.g., continual vs. limited exposure) can influence self-administration behavior. For
these reasons, among others (e.g., subject drug history), determination of relative reinforcement
efficacy between drugs can be arduous (Balster, 1991).
A subsequent extension of these studies sought to determine whether previous exposure
to cocaine might have influenced results reported by Tanda et al. (2000). Thus, drug naïve
squirrel monkeys were employed in a similar paradigm and THC was evaluated for its ability to
maintain self-administration behavior. Monkeys were trained to lever press (FR10; 60 s timeout)
for an infusion of 4 µg/kg THC, the dose that previously maintained self-administration
behavior. This dose did indeed maintain self-administration behavior, and subjects responded at
a near maximal rate given the reinforcement contingencies. Once baseline responding for this
dose was established, a 5 day vehicle substitution was conducted in between each assessment in
the dose effect determination (1-16 µg/kg/infusion). Only 2, 4 and 8 µg/kg/infusion doses
resulted in a significantly higher number of infusions per session compared to vehicle. Although
rates of responding for THC 16 µg/kg/infusion were not significantly different than vehicle
responding, subjects still responded for this high dose and administered a higher cumulative
quantity of THC in the high dose condition relative to all other doses tested. In sum, THC is selfadministered in humans, as well as non-human primates (under certain conditions), illustrating
the reinforcing efficacy of cannabinoids.
The synthetic cannabinoid WIN 55,212-2, a potent full agonist (compared to the plantderived partial agonist THC) is self-administered in rodents. Both rats (Fattore, Cossu,
Martellotta, & Fratta, 2001) and mice (Martellotta, Cossu, Fattore, Gessa, & Fratta, 1998) selfadminister WIN 55,212-2 in a dose-dependent manner. Microdialysis results from rats
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demonstrate that WIN 55,212-2 self-administration also elevates extracellular dopamine in the
shell and core of the nucleus accumbens (Lecca, Cacciapaglia, Valentini, & Di Chiara, 2006).
Interestingly, onset of this elevation occurs more rapidly, persists longer and at a greater
magnitude in the shell than the core (Lecca et al., 2006). Under extinction conditions, however,
dopamine dialysate levels remain unchanged from baseline in both regions, despite the presence
of lever-pressing behavior. These microdialysis findings conducted in animals self-administering
cannabinoids support the role of the nucleus accumbens shell in the reinforcing properties of
drugs with abuse liability (for review, see Di Chiara, 2002).
Intoxicating properties of cannabinoid agonists
The drug discrimination paradigm has been used extensively as a preclinical model for
the subjective effects produced by a drug. Based on the principle that certain drugs are capable of
serving as discriminative stimuli (i.e., the interoceptive stimuli produced by one drug can be
discerned from a non-drug or other drug state), this model typically features an animal trained to
make one response (e.g., lever press) after injection of a drug (“training drug”) and make a
different response (e.g., pressing a different lever) under the presence of vehicle, usually for food
reward. Once the animal can reliably discriminate between the discriminative stimulus effects
produced by these two distinct states, they can be administered novel compounds to determine
whether they elicit discriminative stimulus effects similar to or different than that of the training
drug. Drug discrimination research has provided insight on numerous characteristics of drugs,
including agonist/antagonist receptor interactions, structure activity relationships, and
pharmacokinetics (for review, see Colpaert, 1999).
THC has typically served as the drug of reference for cannabinoid discrimination studies.
THC discrimination is believed to model the intoxicating properties produced by marijuana
4

(Balster & Prescott, 1992) and has been established in numerous species, including rats (Jarbe,
Johansson, & Henriksson, 1976; Semjonow & Binder, 1985; Wiley, Barrett, Lowe, Balster, &
Martin, 1995b; Burkey & Nation, 1997), non-human primates (Gold, Balster, Barrett, Britt, &
Martin, 1992; Wiley, Barrett, Britt, Balster, & Martin, 1993; Wiley, Huffman, Balster, & Martin,
1995a; Wiley, Lowe, Balster, & Martin, 1995b; McMahon, 2009), pigeons (Henriksson,
Johansson, & Jarbe, 1975; Jarbe & Hiltunen, 1988; Mansbach, Rovetti, Winston, & Lowe,
1996), and mice (McMahon, Ginsburg, & Lamb, 2008; Vann et al., 2009b; Long et al., 2009).
Several key findings strongly suggest that the discriminative stimulus properties of THC
are mediated through CB1 receptor activity. First, the discriminative stimulus of the
phytocannabinoid THC is engendered by structurally dissimilar synthetic cannabinoids,
including the bicyclic compound CP 55,940 and the indole derivative WIN 55,212-2 (Gold et al.,
1992; McMahon et al., 2008). Tests with a number of bicyclic analogs (Compton et al., 1993)
and indole derivatives (Vann et al., 2009a) have revealed a strong correlation between CB1
receptor affinity and ability to occasion THC-appropriate responding. Further, non-cannabinoid
agents from a variety of distinct pharmacological classes fail to substitute for THC (Browne &
Weissman, 1981; Barrett, Wiley, Balster, & Martin, 1995; Wiley et al., 1995a). Lastly,
rimonabant readily attenuates THC’s discriminative stimulus in all of the aforementioned species
(Wiley et al., 1995b; Mansbach et al., 1996; McMahon et al., 2008).
Less clear is the extent to which endocannabinoids may produce THC-like intoxication.
Due to rapid degradation of endocannabinoids, it has frequently been difficult to discern to what
extent observed differences between THC and endocannabinoid effects may be contributed to
pharmacodynamic, rather than pharmacokinetic, factors. Anandamide unreliably substitutes for
THC, typically at doses that severely inhibit operant responding (Wiley, Balster, & Martin, 1995;
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Solinas et al., 2007b). Several strategies to combat the metabolic instability of endocannabinoids
have been developed, including more stable anandamide analogs, such as methanandamide,
pharmacologic inhibitors of FAAH and/or MAGL, and transgenic mice lacking enzymes for
endocannabinoid hydrolysis (i.e., FAAH -/-). Together, these approaches have offered greater
insight into the subjective effects of THC, anandamide, and to a lesser extent, 2-AG.
Methanandamide substitution for THC appears to be, in part, determined by the THC
training dose used. Jarbe et al. (1998) reported that methanandamide substitutes for low (1.8
mg/kg, 3.0 mg/kg), but not high (5.6 mg/kg) training doses of THC. This finding has been
replicated and reported by others in rats (Burkey & Nation, 1997; Jarbe, Lamb, Lin, &
Makriyannis, 2000), non-human primates (McMahon, 2009) and mice (unpublished data from
our lab). Additionally, THC fully substitutes for methanandamide in rats (Jarbe, Lamb, Lin, &
Makriyannis, 2001; Wiley et al., 2004), demonstrating cross-substitution between the
discriminative stimulus effects of THC and an anandamide analog. In drug discrimination,
demonstration of cross-substitution is a key indicator that drugs exert intoxicating effects that are
mediated through similar or identical mechanisms. Such determinations have provided critical
support in classifying both existing and newly developed drugs. Disparities between
discriminative stimulus properties of THC and anandamide are frequently attributed to the
latter’s activity at non-cannabinoid sites, notably transient receptor potential vanilloid type 1
(TrpV1) receptors.
Pharmacological inhibition of FAAH, in conjunction with exogenously administered
anandamide, also results in full substitution for THC in rats (Solinas et al., 2007b) and mice
(Vann et al., 2009a). In THC-trained FAAH -/- mice, administration of MAGL inhibitor JZL184
resulted in full substitution for THC (Long et al., 2009). In wild-type counterparts, JZL184
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produced approximately 50% THC-appropriate responding, suggesting upregulated anandamide
levels in FAAH -/- mice were responsible for this discrepancy in JZL184 substitution patterns
(Long et al., 2009). This notion was supported following testing with JZL195, an inhibitor of
FAAH and MAGL, which produced nearly equivalent levels of THC-appropriate responding in
both genotypes (Long et al., 2009).
Recent work from our lab demonstrated that anandamide could serve as a discriminative
stimulus in FAAH -/- mice, with anandamide’s discriminative stimulus generalizing to THC, but
not the fatty acid amide oleamide (Long et al., 2009). In the same study, rimonabant challenge
significantly attenuated responding on the anandamide-paired lever for both anandamide and
THC, lending further evidence to CB1 mediation of cannabinoid discriminative stimulus effects.
Additional unpublished data from our lab collected in anandamide-trained FAAH -/- mice show
that indirect elevation of brain 2-AG levels via the MAGL inhibitor JZL184 also produced full
substitution for anandamide, highlighting similarities between the subjective effects evoked by
endocannabinoids and plant-derived cannabinoids. As such, endocannabinoids appear to be able
to elicit THC-like intoxication. Given the mounting interest in endocannabinoid-based
therapeutics, more research is needed to understand the cannabimimetic intoxicating potential of
such treatment strategies.
Although only compounds that act via CB1 mechanisms substitute for THC, diazepam
has been shown to partially engender THC-like responding in rats (Mokler, Nelson, Harris, &
Rosecrans, 1986; Barrett et al., 1995; Wiley & Martin, 1999) and rhesus monkeys (Wiley et al.,
1995a), but not pigeons (Jarbe & Hiltunen, 1988). This finding appears to be attributable to
diazepam activity at GABA, not cannabinoid, receptors, as it was reversed by the GABA
antagonist flumanzenil (Mokler et al., 1986), but not rimonabant (Wiley & Martin, 1999). CB1
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receptors are frequently co-expressed GABAergic neurons (Tsou, Mackie, Sanudo-Pena, &
Walker, 1999), providing a tenable explanation for this finding.
A number of pharmacological agents can modify THC’s discriminative stimulus. The μopioid agonists heroin and morphine, but neither the δ-opioid agonist SNC-80 nor the k-opioid
agonist U50-488, potentiated THC’s discriminative stimulus in rats (Solinas, Zangen, Thiriet, &
Goldberg, 2004; Solinas & Goldberg, 2005a). This effect was reversed with the μ-opioid
antagonist naltrexone, but not by δ- or k-opioid antagonists (Solinas & Goldberg, 2005a).
Additionally, naltrexone shifted the THC dose effect curve rightward, an effect that did not
extend to δ- or k-opioid antagonists (Solinas & Goldberg, 2005a). Since none of these opioid
agonists produced meaningful THC-appropriate responding when given alone, it appears that μopioid receptors can modulate the intoxicating properties of THC.
Similarly, cholinergic and D2 dopaminergic activation can enhance THC’s discriminative
stimulus in rats. Both nicotine and pilocarpine (nicotinic and muscarinic acetylcholine agonists,
respectively) potentiate THC’s discriminative stimulus, but fail to substitute on their own
(Solinas et al., 2007a). Likewise, general dopamine agonists (cocaine, amphetamine) and D2
agonists (quinpirole and apomorphine) also produced a similar pattern (i.e., potentiation, but lack
of substitution) that was not seen with D1 agonists (Solinas, Tanda, Wertheim, & Goldberg,
2010). In sum, substitution for THC is positively correlated with CB1 receptor affinity, reversed
by CB1 antagonists, and non-cannabinoids do not fully substitute for THC, supporting the
precise pharmacological specificity typically offered in drug discrimination experiments.
However, activity at several other receptors has been shown to modify or produce partial
substitution for THC’s discriminative stimulus, reflecting the complex interactions between the
endocannabinoid system and a multitude of other neurochemical systems.
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Rimonabant
The endocannabinoid system’s known involvement in many physiological processes,
including appetite, reward, and cognition, coupled with its interactions with other neurochemical
systems suggest a vast range of potential therapeutic applications for a selective CB1 antagonist.
In 1994, scientists from Sanofi-Aventis reported on the development of the first CB1 antagonist,
SR141716A

(5-(4-Chlorophenyl)-1-(2,4-dichloro-phenyl)-4-methyl-N-(piperidin-1-yl)-1H-

pyrazole-3-carboxamide; hereto referred as rimonabant), which displayed approximately 1000fold selectivity for CB1 over CB2 receptors (Rinaldi-Carmona et al., 1994). In this seminal
report, rimonabant dose-dependently antagonized cannabinoid-induced changes on mouse van
deferens contractions and adenylate cyclase activity in rat brain membranes, and reversed
characteristic cannabinoid behavioral effects, including antinociception, hypothermia, and ring
immobility.
While rimonabant is typically referred to as a selective CB1 antagonist (i.e., possessing
no intrinsic activity at the receptor), there is a body of literature suggesting that rimonabant
functions as an inverse agonist (i.e., exerting pharmacological effects opposite of agonist activity
at the receptor). The first behavioral evidence supporting this theory came from Compton et al.
(1996), who demonstrated that rimonabant stimulated locomotor activity at higher doses (> 3
mg/kg, i.v.). Rimonabant-induced stimulation of locomotor activity could have been due to a
number of factors, including inhibition of endocannabinoid tone or via activity through an
unknown non-CB1 mechanism (Compton et al., 1996). In vitro work also substantiated claims of
rimonabant’s inverse agonist activity as demonstrated by adenylyl cyclase activity (Meschler,
Kraichely, Wilken, & Howlett, 2000) and effects on basal [35S]GTPγS binding (Landsman,
Burkey, Consroe, Roeske, & Yamamura, 1997; Sim-Selley, Brunk, & Selley, 2001).
9

An investigation by Bass and Martin (2002) supported the hypothesis that inverse agonist
properties of rimonabant were not attributable to its ability to stimulate locomotor activity. A
series of rimonabant analogs that displayed inverse agonist activity at CB1 receptors in
[35S]GTPγS binding assays were incapable of stimulating locomotor activity relative to vehicle
controls. Additionally, some rimonabant analogs with low CB1 affinity did not function as
inverse agonists as CB1 receptor inverse agonists, but did increase locomotor activity (Bass et
al., 2002).
Subsequent investigations of rimonabant have vastly aided understanding and
manipulation of the endocannabinoid system. Indeed, utilization of rimonabant as a mechanistic
tool for exploration of the endocannabinoid system has been responsible for many critical
findings that form the underpinnings of cannabinoid pharmacology. The breadth and depth of
such findings are too great as to aspire to review thoroughly. Thus, the following review of
rimonabant’s pharmacological properties will focus on several key areas: 1) rimonabant as a
mechanistic tool to characterize cannabinoid dependence and withdrawal, and data implicating
CB1 receptor antagonism for the treatment of 2) substance abuse disorders and 3) obesity.
Cannabinoid withdrawal
Prior to the synthesis of a selective CB1 receptor antagonist, reports of spontaneous
cannabinoid withdrawal were sparse (McMillan, Dewey, & Harris, 1971; Kaymakcalan, Ayhan,
& Tulunay, 1977; Beardsley, Balster, & Harris, 1986), while others failed to observe withdrawal
(Leite & Carlini, 1974; Harris, Waters, & McLendon, 1974). This mild spontaneous withdrawal
syndrome (relative to other drugs of abuse such as ethanol or cocaine) is likely due to the
relatively long half-life of THC and other cannabinoids (Compton, Dewey, & Martin, 1990).
Shortly after the development of rimonabant, it was reported that it precipitated withdrawal in
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rats following chronic treatment with THC (Aceto, Scates, Lowe, & Martin, 1995; Tsou, Patrick,
& Walker, 1995). Tsou et al. (1995) observed a withdrawal syndrome characterized by
disorganized motor behavior, frequent, but not repetitive, wet dog shakes and forepaw flutters, as
well as increases in grooming behavior, horizontal ambulation and rearing (Tsou et al., 1995).
Other behavioral signs indicative of withdrawal, such as head shakes, facial rubbing, and
stretching have been noted as well (Aceto et al., 1995).
Since these initial findings were reported, rimonabant precipitated withdrawal has been
demonstrated in a number of species and has been extended to other cannabinoids. Indeed, both
exogenous (e.g., WIN 55,212-2; Aceto, Scates, & Martin, 2001) and endogenous (e.g., AEA;
Costa, Giagnoni, & Colleoni, 2000) cannabinoids have been shown to produce physiological
dependence, as indicated by the presence of withdrawal symptoms upon removal of chronic
cannabinoid administration or precipitated withdrawal following rimonabant administration.
Also of note is the ability of direct or indirect activation of the endocannabinoid system to
alleviate withdrawal symptoms. Treatment with either THC or inhibitors of endocannabinoid
hydrolysis during rimonabant-precipitated withdrawal have been shown to reduce the expression
of withdrawal symptoms, such as paw flutters, in mice (Lichtman, Fisher, & Martin, 2001;
Schlosburg et al., 2009). Accordingly, rimonabant has served as a valuable pharmacological tool
in determining the ability of cannabinoids to produce physiological dependence. Further, this
model provides a means for evaluating putative pharmacotherapies for the treatment of cannabis
dependence.
Discriminative stimulus properties of rimonabant
One significant objective of studying cannabinoid dependence is to develop strategies for
treatment of the withdrawal symptomology. Though early attempts to train rimonabant were
11

largely unsuccessful (Wiley, 1999), McMahon and France (2003) established rimonabant as a
discriminative stimulus in rhesus monkeys chronically treated with THC (1.12 mg/kg/day). In
this regard, the discriminative stimulus effects produced under this dosing regiment arguably
serve as another avenue to model cannabis withdrawal, and consequently evaluate therapeutic
agents for its treatment. Monkeys were trained to press one lever following administration of
rimonabant (1 mg/kg) and press another lever following vehicle to avoid an electric foot shock.
Once stimulus control was established, it was demonstrated that rimonabant’s discriminative
stimulus was dose-dependent, and discontinuation of chronic THC treatment engendered
rimonabant-like responding alone. This effect was reversed once THC treatment was resumed.
Further, THC (in addition to the chronic regimen) dose-dependently attenuated rimonabant’s
discriminative stimulus, whereas cocaine and ketamine failed to substitute for rimonabant,
demonstrating the pharmacological specificity of rimonabant’s discriminative stimulus.
In a subsequent study, it was shown that the potent synthetic cannabinoid, CP 55,940,
also fully blocked rimonabant’s discriminative stimulus, whereas WIN 55,212-2, another potent
synthetic cannabinoid, only did so partially (Stewart & McMahon, 2010). Additionally, the α2adrenergic agonist clonidine, but not the GABAA positive allosteric modulator, diazepam,
partially attenuated rimonabant’s discriminative stimulus, suggesting that clonidine may be a
viable treatment option for the subjective dysphoria present in cannabis withdrawal (Stewart &
McMahon, 2010). Indeed, a study conducted in individuals meeting criteria for cannabis
dependence found that a combination of THC and lofexidine (another α2-adrenergic agonist)
significantly attenuated a number of subjective (e.g., marijuana craving, irritability, quality of
sleep) and objective (e.g., latency to fall asleep, percentage of time spent sleeping) withdrawal
measures during a period of cannabis abstinence (Haney et al., 2008). This combination appeared

12

more efficacious relative to either drug alone or vehicle and elicited a “neutral” feeling for the
subjective effects rating, whereas individuals reported liking the subjective effects produced by
THC alone. Together, these findings promote further investigations of α2-adrenergic agonists for
their therapeutic potential, either alone or as an adjunctive treatment for cannabis withdrawal.
Rimonabant has also been trained as a discriminative stimulus using discriminative taste
aversion procedure (Jarbe, Harris, Li, Liu, & Makriyannis, 2004; Jarbe, Li, Vadivel, &
Makriyannis, 2008). In contrast with more traditionally utilized operant based drug
discrimination paradigm, discriminative taste aversion is based upon Pavlovian conditioning
principles. In this model, rats were treated with 5.6 mg/kg rimonabant, given access to drinking
water, and then treated with lithium chloride, a noxious stimulus that markedly decreased
drinking behavior (i.e., unconditioned response). During another pairing session, subjects were
treated with saline, given access to drinking water, and then received another injection of saline.
Future rimonabant administration resulted in significantly less drinking behavior compared to
saline. Thus, rimonabant served as a conditioned stimulus and could dose-dependently elicit the
same effect as the unconditioned stimulus, lithium chloride (Jarbe et al., 2004). AM251, a CB1
antagonist, produced a rimonabant-like decrease drinking behavior, whereas THC and the CB2
antagonist SR144528 produced levels of drinking similar to saline (Jarbe et al., 2004). When coadministered with rimonabant, THC dose-dependently attenuated the decrement in drinking
behavior (Jarbe et al., 2004). Collectively, these results indicate that rimonabant can exhibit
cannabinoid-mediated discriminative stimulus effects following certain methodological
manipulations.
Therapeutic potential for non-cannabinoid drug abuse disorders
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CB1 receptors are located abundantly throughout the central nervous system and are
frequently co-localized with other receptors. Particularly noteworthy is that CB1 receptors are
prevalent among brain areas associated with reward, such as the nucleus accumbens. In vivo
microdialysis has demonstrated that anandamide and methanandamide (a metabolically stable
analog of anandamide) elevate levels of DA in the shell of the nucleus accumbens (Solinas et al.,
2006). In the same study, inhibition of FAAH (via URB597 pretreatment) potentiated
anandamide-induced release of DA, although URB597 had no effects on DA release when given
alone. Rimonabant, but not the TrpV1 antagonist capsazepine, reversed these effects, strongly
implicating CB1 receptor activity in reward processes. Thus, the endocannabinoid system likely
exerts modulatory effects over systems regulating drug abuse behavior and may attenuate reward
processes attributed to other abused drugs.
A number of studies have suggested a potential role for rimonabant in nicotine cessation
therapy. For instance, a dose effect determination of rimonabant (0.03-1 mg/kg) pretreatment on
nicotine self-administration (0.03 mg/kg/infusion) in rats revealed a dose-and trial-dependent
decrease in responses on the active lever and number of infusions (Cohen et al., 2002). The low
dose of rimonabant (0.03 mg/kg) failed to alter self-administration behavior. The 0.1 mg/kg dose
of rimonabant decreased responding on the active lever and infusions on the second trial, but not
the first, whereas 0.3 and 1 mg/kg did so on both the first and second trials. However, presses on
the inactive lever were significantly decreased by rimonabant on trial 1 (1 mg/kg) and 2 (0.3
mg/kg), suggesting potential motor disruptions at these higher doses. Further, in the same study,
conducted by scientists at Sanofi-Aventis, rimonabant failed to block nicotine’s discriminative
stimulus in nicotine-trained rats (Cohen et al., 2002). Interestingly, nicotine substitution for damphetamine was reversed by rimonabant (3 mg/kg). In vivo microdialysis revealed significant
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attenuation of nicotinic enhancement of extracellular dopamine in both the shell and bed nucleus
of the stria terminalis of the nucleus accumbens (Cohen et al. 2002). These results suggest that
rimonabant might attenuate some of the reinforcing, but not subjective, effects of nicotine
through a dopaminergic mechanism.
Rimonabant (3 mg/kg) also has been shown to block the development of nicotine
conditioned place preference (CPP), as well its expression in rats. Acute rimonabant only
abolished expression of nicotine CPP 24h removed from the last conditioning trial (Forget,
Hamon, & Thiebot, 2005). Conversely, chronic rimonabant treatment blocked expression of
nicotine CPP 2-3 weeks following conditioning. Locomotor activity was decreased during all
nicotine conditioning trials in rats pretreated with rimonabant, relative to nicotine alone, thus
clouding interpretation of these findings. Further, the anhedonic properties associated with
rimonabant (e.g., Beyer et al., 2010; Horder, Harmer, Cowen, & McCabe, 2010) are another
important consideration when evaluating its effects in CPP experiments, especially given the
disparities between acute and chronic rimonabant treatment on expression of nicotine CPP.
One factor commonly attributed to nicotine relapse is the weight gain users frequently
experience during quit attempts (Williamson et al., 1991). Existing treatment strategies are either
only temporarily effective (e.g., buproprion; Hurt et al., 1997; Jorenby et al., 1999) or
inconsistent (e.g., nicotine replacement therapy; Perkins, 1993) in attenuating weight gain
induced by tobacco abstinence. Coupled with its noted effects on appetite, rimonabant’s efficacy
in preclinical models of nicotine reward and dependence made it an attractive clinical target for
treatment of nicotine dependence. Indeed, rimonabant progressed to Phase III clinical trials to
evaluate its efficacy and safety alone (studies with rimonabant and tobacco use; STRATUS) and
as an adjunct to nicotine replacement therapy (Rigotti, Gonzales, Dale, Lawrence, & Chang,
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2009). Given alone, 20 mg rimonabant daily facilitated tobacco abstinence during a 10 week
treatment period, with 36% of patients remaining abstinent relative to those receiving 5 mg
rimonabant (20.2%) or placebo (20.6%). Nausea was reported in nearly 16% of the 20 mg group,
but only in 9.2% of the placebo group. Moreover, a higher attrition rate was noted in those taking
20 mg rimonabant compared to placebo (6.9 vs. 3.8%, respectively). Rimonabant was also more
effective in preventing relapse in combination with a nicotine patch (39.0%) versus rimonabant
alone (21.3%, Rigotti et al., 2009). Weight gain at the end of treatment was negligible (< 0.5 kg)
for both treatment groups and a similar number of adverse incidents were reported between
groups (Rigotti et al., 2009). Specifically, depression and anxiety were noted in 4.2 and 5.8% of
patients, respectively, with approximately 2% of patients discontinuing treatment due to the
severity of depression or anxiety experienced. One patient (out of 754) attempted suicide (Rigotti
et al., 2009).
Results from clinical studies suggested rimonabant to be moderately efficacious in
treating nicotine dependence, especially in preventing post-abstinence weight gain.
Unfortunately, the propensity of rimonabant to produce nausea and more importantly, psychiatric
symptoms, dampened enthusiasm for this treatment strategy. By the time Rigotti and colleagues
(2009) published their findings, rimonabant had already been withdrawn from all markets by
Sanofi-Aventis, as discussed later. Nonetheless, given the importance of developing novel
treatment strategies for nicotine dependence, the benefit to risk ratio of rimonabant arguably
warrants further discussion and exploration of CB1 antagonists as clinical targets.
Preclinical data also suggest a role for CB1 antagonists in the treatment of several other
substance abuse disorders. For instance, opiate self-administration in rats is frequently attenuated
by rimonabant (Braida, Pozzi, Parolaro, & Sala, 2001; Caille & Parsons, 2003; De Vries,
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Homberg, Binnekade, Raaso, & Schoffelmeer, 2003; Solinas, Panlilio, Antoniou, Pappas, &
Goldberg, 2003). Caille and Parsons (2006) utilized in vivo microdialysis and self-administration
techniques to investigate neural mechanisms that may be responsible for this observation. Two
key brain regions known to influence opioid reward are the nucleus accumbens and its
projections to the vental pallidum. Opiate administration inhibits neuronal GABA activity,
consequently reducing GABA efflux in the vental pallidum. Moreover, heroin selfadministration is blocked by pharmacological enhancement of GABA in the vental pallidum
(Bardo, 1998), providing evidence that agents that restore GABA activity might be clinically
relevant for treatment of opioid dependence.
In vivo microdialysis revealed the rimonabant dose-dependently reversed morphineinduced decreases in vental pallidum GABA efflux, but did not alter interstitial DA increases in
the nucleus accumbens shell (Caille & Parsons, 2006). Furthermore, rimonabant had no effect on
cocaine-induced changes to GABA or DA in the vental pallidum or nucleus accumbens shell,
respectively. Bilateral administration of rimonabant in the nucleus accumbens, but not vental
pallidum, attenuated heroin self-administration (Caille & Parsons, 2006). Together, these results
suggested that rimonabant exerts its effects on opioid self-administration independent of
dopaminergic activity.
Another prospective utility for CB1 antagonists is for the treatment of alcoholism. A
litany of preclinical data has demonstrated rimonabant’s efficacy in numerous assays of alcoholrelated behavior (for review, see Colombo et al., 2007). A pioneering study from George Kunos’
laboratory revealed many key findings regarding interactions between the endocannabinoid
system, age and ethanol intake (Wang, Liu, Harvey-White, Zimmer, & Kunos, 2003).
Pharmacologic or genetic inhibition (i.e., CB1 -/-) of CB1 receptor activity was shown to reduce
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ethanol preference in a two-bottle choice paradigm in younger (6-10 week old) wild-type
C57BL/6 mice (Wang et al., 2003). Alcohol preference in mature (26-48 week old) mice was
reduced compared to younger mice and rimonabant had no effect on ethanol intake or preference
in either genotype at this age range (Wang et al., 2003). No significant age-related differences in
CB1 receptor density were noted in a variety of brain regions, including cerebellum, limbic
forebrain, amygdala and hypothalamus. However, agonist-stimulated binding was decreased in
the limbic forebrain samples (containing nucleus accumbens and anterior cingulate cortex) of old
mice relative to young mice, suggesting that the age-related decline in ethanol preference might
coincide with decreases in CB1 receptor signaling (Wang et al., 2003).
A clinical study of rimonabant’s efficacy in individuals meeting DSM-IV criteria for
alcohol dependence conducted in Northern Europe found a non-significant trend of rimonabant
(20 mg/day) to increase time to first drink and first heavy drinking period (4 drinks in females, 6
in males) (Soyka et al., 2008). The authors suggested the short treatment period and large
percentage of placebo patients who failed to relapse (40.3%) as factors that might have
contributed to the observed lack of efficacy of rimonabant. Attrition rates were similar across
treatment groups, but discontinuation rates due to treatment-emergent adverse events were higher
in patients receiving placebo (7.9%) than rimonabant (4.6%) (Soyka et al., 2008). Additionally, 3
suicide attempts were reported in placebo patients compared to 1 in the experimental group
(groups contained a near-identical number of subjects). Although rimonabant failed to
significantly improve the primary outcome measures in this report, the relatively low incidence
of adverse effects, especially suicide attempts, is an equally important finding.
Appetite Regulation
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Perhaps the most promising application for rimonabant was for treatment of obesity.
Preclinical data indicated rimonabant decreased food consumption and body weight in free
feeding rats, but did not alter water intake (Colombo et al., 1998). Rimonabant also diminished
food-maintained operant responding and free feeding access across a variety of diets (high fat,
high carbohydrate, standard chow) in rats (high fat, high carbohydrate, standard chow;
McLaughlin et al., 2003). In mice, genetic deletion of CB1 receptors resulted in lower
progressive ratio breakpoints in operant responding maintained by a sweet reinforcer (Ensure)
compared to wild-type mice (Ward & Dykstra, 2005). This enhanced preference for a sweet
reward in wild-type mice was abolished by rimonabant challenge (Ward & Dykstra, 2005). No
differences in breakpoints maintained by fat (corn oil) reinforcer were noted between genotypes.
In fasted mice, rimonabant dose-dependently decreased chow consumption without disrupting
locomotor activity and reversed THC-induced increases in food consumption (Wiley et al.,
2005). Foltin and Haney (2007) reported that rimonabant and amphetamine decreased intake of
both standard food pellets and pieces of candy in non-human primates. Amphetamine also
increased the latency to obtain the first food pellet, but not candy, whereas rimonabant did not
alter the latency to obtain either reinforcer (Foltin & Haney, 2007). Hence, differential effects of
rimonabant on food type have been noted by some (Ward & Dykstra, 2005), but not others
(McLaughlin et al., 2003; Foltin & Haney, 2007). These discrepancies may be attributable to any
number of differences between studies, such as species, reinforcement schedule, and consistency
of reinforcer (liquid vs. solid). Collectively, these and other preclinical findings demonstrating
rimonabant’s efficacy in attenuating feeding behavior necessitated research in the clinical
domain.
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Sanofi-Aventis proceeded with a series of rimonabant in obesity (RIO) clinical trials to
evaluate rimonabant’s efficacy and safety as an anti-obesity agent. These trials were 1 or 2 years
in duration with primary endpoints being weight loss and weight maintenance. A meta-analysis
of the RIO studies found that patients receiving 20 mg/day rimonabant lost significantly more
weight than the placebo group (Christensen, Kristensen, Bartels, Bliddal, & Astrup, 2007). This
effect was consistent across all 4 trials, with those receiving rimonabant being 5 times more
likely to lose > 10% of their body weight (Christensen et al., 2007). Baseline and subsequent
quarterly assessments of mood were collected using the hospital and anxiety depression scale
(HADS). A significant increase in anxiety, but not depression, score was noted for the
experimental group (Christensen et al., 2007). However, assessment of total adverse events
revealed a higher incidence of adverse events in rimonabant patients (86.0% compared to 81.8%
in placebo group; Christensen et al., 2007). Further analysis of these data revealed significantly
higher attrition rates in rimonabant patients attributed to depressed mood disorders and anxiety
(Christensen et al., 2007).
As part of its meta-analysis efforts, the U.S. Food and Drug Administration (FDA)
commissioned an independent review of source documentation, whereby suicidality events were
inferred from patient narratives. A total 66 cases were flagged as possible or definite cases of
suicidality between placebo (n=20) and rimonabant patients (46). The majority of cases were
classified as suicidal ideation, with rimonabant patients 3 times more likely to experience
suicidal ideation than placebo (n=39 vs. 13, respectively). These findings ultimately led to
rimonabant being withdrawn from the market in the European Union in early 2009. However,
only 4 cases of attempted suicide were noted in the rimonabant group, relative to 7 attempts in
the placebo group. Moreover, a significant number of patients seeking treatment for obesity also
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experience depression (Wadden et al., 2001), making this a particularly vulnerable population for
adverse psychiatric events.
The case for rimonabant and further exploration of CB1 receptor antagonists
Rimonabant has clinically validated efficacy in combating the three leading preventable
causes of death in the U.S.: obesity, tobacco and alcohol-related illnesses (Mokdad, Marks,
Stroup, & Gerberding, 2004). These global threats to health manifest themselves in myriad wellreported medical consequences, such as heart disease, type 2 diabetes, lung cancer, liver
cirrhosis, and deaths attributed to alcohol overdose or automobile accidents. The therapeutic
potential of CB1 antagonists previously described in these and other areas provide a compelling
argument to continue to pursue a target in these areas. A neutral antagonist, for example, might
be predicted to lack the psychiatric-related issues reported for rimonabant in clinical trials.
Although drug manufacturers are understandably reluctant to pursue such efforts following the
withdrawal of rimonabant from the market, the hypothetical benefits of a CB1 antagonist in a
number of therapeutic situations warrant further research to this end.
Pharmacological profile of rimonabant analogs
Following the successful development of the CB1 antagonist rimonabant and subsequent
characterization of its pharmacological profile, attempts to create rimonabant analogs were
initiated. Indeed, evaluating the structure-activity relationship (i.e., evaluating how
manipulations to a compound’s chemical structure alter its behavioral and neurochemical effects)
of rimonabant can provide valuable information pertinent to the actions of the parent compound
and also lead to the discovery of more specific and/or potent CB1 antagonists. Thus,
development and testing of rimonabant analogs serves as an avenue towards further
understanding cannabinoid pharmacology and possible discovery of new preclinical tools with
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potential therapeutic applications. Several structure-activity relationship reports on rimonabant
analogs retaining the central pyrazole core of the parent compound (see Figure 1) have provided
insight into their neurochemical and behavioral activity.
Two of these reports focused on a series of pyrazole rimonabant analogs (synthesized by
Organix Inc.) that investigated their binding affinity at CB1 receptors, and ability to elicit or
attenuate cannabimimetic effects in the mouse tetrad. Drugs that produce hypothermia, catalepsy,
antinociception and inhibit spontaneous activity (tests that comprise the tetrad) at similar doses
are likely to possess cannabinergic activity (Martin et al., 1991). These effects are reversed by
the CB1 antagonist, rimonabant (Compton et al., 1996), but not by the CB2 antagonist SR144528
(Wiley et al., 2002). Furthermore, agonist potency for producing these effects is correlated with
CB1 binding affinity in the brain (Compton et al., 1993; Adams et al., 1995; Wiley et al., 1998).
These findings, in conjunction with the high distribution of CB1 receptors throughout the central
nervous system relative to peripherally located CB1 receptors (Pertwee, 1997), strongly suggest
that activity of cannabinoid agonists in the tetrad is mediated via central CB1 receptors. Thus,
the tetrad has served as a very useful tool in evaluating structure-activity relationships (SAR) of
different cannabinoids and understanding requirements for CB1 receptor recognition and
activation.
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Figure 1. Chemical structure of rimonabant. Points of attachment for substituents of the
pyrazole core are denoted in red.
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A series of four compounds synthesized by Organix Inc. with 1-substitutent
replacements functioned as antagonists or inverse agonists in [35S]GTPγS binding assays (Bass et
al., 2002). Not surprisingly, none of these compounds produced tetrad effects on their own;
however, only the compound with the highest affinity for CB1 receptors from this series, O1253, antagonized THC’s effects in the tetrad (Wiley et al., 2001). While a low dose (1 mg/kg)
of O-1253 blocked THC-induced hypolocomotion, challenge tests with a higher dose (10 mg/kg)
stimulated activity (Wiley et al., 2001). When given alone, O-1253 failed to alter locomotor
activity (Wiley et al., 2001; Bass et al., 2002). Howlett et al. (2000) reported on two compounds
featuring an azido or isothiocyanato substitution in the 1-position that functioned as CB1
receptor antagonists in [35S]GTPγS binding, but at concentrations higher than expected based on
their affinity. Interestingly, these compounds also inhibited adenylyl cyclase activity in
neuroblastoma cell membranes (Howlett et al., 2000), an effect typically produced by
cannabinoid agonists (Howlett & Fleming, 1984). Another investigation of 1-substituent analogs
studied revealed that a 2,4-dicholorophenyl substitution produced optimal CB1 receptor affinity
relative to other replacements, and functioned as a competitive antagonist in several in vitro
assays (Lan et al., 1999). When evaluated together, rimonabant analogs with 1-substituent
manipulations retain the antagonist/inverse agonist activity of the parent compound in most in
vitro assays, but their ability to reverse THC’s tetrad effects was often precluded by poor CB1
receptor affinity.
Work from Wiley et al. (2001) revealed that rimonabant analogs with replacements in the
5- and/or 4-substituent maintained good affinity for the CB1 receptor and readily blocked THC’s
tetrad effects. One noted exception to this was O-1559, which featured an alkyl group in position
5 in place of the phenyl ring in position 5 and possessed markedly lower CB1 receptor affinity,
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providing evidence that the phenyl ring in position 5 is heavily implicated in CB1 receptor
recognition (Wiley et al., 2001). Only one compound from this series, O-1710, produced inverse
agonist activity in [35S]GTPγS binding assays, but decreased locomotor activity during the first
hour compared to the vehicle treated cohort (Bass et al., 2002).
Another interesting compound from this series was O-1691, which featured an alkyl
group attached to the phenyl ring in position 5 and replaced the 4-methyl group in position 4
with a bromine. This compound possessed strong CB1 receptor affinity (as did others with an
alkyl group attached to the phenyl ring in position 5), stimulated locomotor activity alone, and
functioned as an antagonist in [35S]GTPγS binding (Bass et al., 2002). Moreover, O1691 reversed
THC-induced antinociception and hypothermia, but failed to ameliorate THC-induced
hypolocomotion (Wiley et al., 2001). One potential interpretation of these findings is that the
locomotor effects of rimonabant and its analogs occurs independently of CB1 receptor binding,
as no significant correlation was found between CB1 affinity and locomotor counts (Bass et al.,
2002). Alternatively, these seemingly discrepant locomotor findings may also be attributable to
variations in the locomotor protocols used. Bass et al. (2002) evaluated locomotor activity across
2 h, compared to a 10 min session utilized in the tetrad studies (Wiley et al., 2001). Another
series of 5-substituent analogs synthesized revealed that a para-substitution produced enhanced
CB1 receptor affinity and selectivity relative to compounds with ortho-substitutions (Lan et al.,
1999).
Results from molecular modeling suggest possible overlap between the para-position of
the 5-substituent of rimonabant and the pentyl side chain of THC (Thomas, Gilliam, Burch,
Roche, & Seltzman, 1998). SAR investigations of this pentyl side chain have revealed its
importance in CB1 receptor affinity (Compton et al., 1993; Martin et al., 1999). In the same vein,
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SAR studies with rimonabant analogs also have demonstrated the importance of the phenyl
group in the 5-substituent as being a critical determinant of CB1 receptor affinity. For example,
replacement of the phenyl group with an alkyl group decreased CB1 receptor affinity by nearly
two orders of magnitude compared to an otherwise identical compound retaining the phenyl
group (O-1559 vs. O-1690; Bass et al., 2002). In sum, changes in the 1-, or 5- (with or without
concomitant changes in position 4) substituent can influence CB1 binding affinity, and
consequently, behavioral activity. Such compounds also retain antagonist or inverse agonist
activity based on in vitro screens. Thus, these positions on the pyrazole core of rimonabant
appear to be involved in CB1 receptor recognition and antagonism.
Perhaps the most interesting finding from investigations of these pyrazole compounds is
that certain alterations in position 3 could elicit agonist or partial agonist-like effects in mice
(Wiley et al., 2001). Specifically, some compounds with carbon chain 3-substituent
replacements, such as O-1269 and O-1270, produced significant decreases in locomotor activity
(Bass et al., 2002) and body temperature and increased tail flick latencies (Wiley et al., 2001).
While only a few compounds from this series elicited cannabimimetic activity, subsequent SAR
investigations of other 3-substituent rimonabant analogs have revealed a number of other
compounds with similar activity. For example, O-4332, O-6629 and O-6658 have varying
degrees of CB1 receptor affinity and exhibit agonist-like activity in the tetrad (see Table 1).
O-6629

(5-Bromomethyl-2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-

pyrazol-3-yl]-4,5-dihydrooxazole) and O-6658 (5-Azidomethyl-2-[5-(4-chlorophenyl)-1-(2,4dichlorophenyl)-4-methyl-1H-pyrazol-3-yl]-4,5-dihydrooxazole)

share

similar

chemical

structures, featuring a bromine or azido substitution in place of the amide group in position 3,
respectively. Results from displacement experiments with radiolabeled CP55,940 and
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rimonabant demonstrate an approximate 2-fold enhanced CB1 receptor affinity for O-6629
compared to O-6658. Based on their relative CB1 receptor affinity, it was initially speculated
that these 3-substituent manipulations conferred cannabinoid agonist properties. However, the
inability of rimonabant to reverse the tetrad effects elicited by such compounds did not support
that conclusion (JL Wiley, unpublished data).
While the tetrad is a quick and efficient preclinical screen for assessing potential
cannabinoid agonist activity, other false positives have been noted. Many drug classes elicit one
or more effects evaluated in the tetrad (e.g., opioid-induced antinociception) and several
antipsychotic drugs (used primarily to treat schizophrenia) produce activity in all four assays
(Wiley & Martin, 2003). For example, chlorpromazine, a first-generation antipsychotic,
generated tetrad activity with similar potencies noted across all tests. Rimonabant did not reverse
antipsychotic-induced tetrad activity, demonstrating that, while non-cannabinoid agents can
appear as false positives in this model (Wiley & Martin, 2003), their effects are not blocked by a
CB1 antagonist. Thus, the tetrad is arguably more accurate in ruling out, rather than
demonstrating, cannabinoid activity (Wiley & Martin, 2003).
Like chlorpromazine, the behavioral activity produced by 3-substituent pyrazole analogs
such as O-6629 is not attenuated by a range of rimonabant doses (1-10 mg/kg), Further, these
behavioral effects are observed in CB1 knockout mice, suggesting that these compounds are
acting independently of established cannabinoid mechanisms. Given the numerous complex
interactions between endocannabinoid signaling and other neurochemical targets, the latter
hypothesis is certainly reasonable. Combined with the scarcity of published information
pertaining to 3-substituent rimonabant analogs and lack of in vitro data suggesting additional
sites of action, evaluating these compounds in drug discrimination will serve as an initial avenue
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towards investigating potential mechanism/s for their behavioral activity. The paradoxical nature
of these compounds (i.e., rimonabant analogs that produce THC-like effects in vivo not mediated
via established cannabinoid mechanisms) provides an interesting challenge in better
understanding the unique pharmacology of these compounds. Therefore, this study is intended to
help illuminate the unexpected behavioral effects and mechanism/s of action produced by these
rimonabant analogs with 3-substituent substitutions.
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Table 1. Pharmacological profiles of selected cannabinoid agents and pyrazole-derived rimonabant analogs
CB1 Affinity (Ki)$

CB1 Pharmacodynamics

Tetrad activity

THC

37.0a

Partial agonist

Yes

WIN 55,212-

2.5a

Full efficacy agonist

Yes

6.2a

Antagonist/

No, reverses THC
tetrad activity

Drug

Chemical Structure

2

Rimonabant

inverse agonist

29

Drug

Chemical Structure

CB1 Affinity (Ki)$

CB1 Pharmacodynamics

Tetrad Activity

38.4b

Unknownb

Yesb

47.5b

Unknownb

Yesb

483.8b

Unknownb

Yesb

O-6629
3-substituent
N
O

H3C

O-6658
3-substituent

Cl

N

N3

N
Cl

Cl

O-4332
3-substituent

$ CB1 binding affinity determined by [3H]CP55,940 displacement. All values reported are expressed as nM.
a. Thomas et al., 1998; b. JL Wiley, unpublished data.
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Rationale
The endocannabinoid system is involved in numerous physiological processes and
engaged in extensive interactions with other neurochemical systems. The development of the
selective CB1 receptor antagonist, rimonabant, provided a much-needed pharmacological tool
for mechanistic study of the endocannabinoid system and exploration of its complex nature.
Given the well-known effects of cannabinoid agonists on appetite, reward and drug abuse-related
behavior, a variety of therapeutic applications for CB1 antagonists have been proposed.
Preclinical and clinical data have supported this hypothesis, demonstrating rimonabant’s efficacy
as an anti-obesity pharmacotherapy, as well as a putative treatment for nicotine, opioid and
alcohol dependence. The health risks associated with these conditions cannot be understated:
Obesity, along with tobacco and alcohol use, are the top three leading preventable causes of
death in the United States (Mokdad et al., 2004) and contribute immensely to disease and death
globally (Lopez, Mathers, Ezzati, Jamison, & Murray, 2006). Existing treatment options are
clearly not sufficient to curb the high number of deaths and illnesses attributed to these factors.
Unfortunately, the emergence of adverse psychiatric events during clinical trials with
rimonabant, including increased risk of suicidal ideation, led to manufacturer Sanofi-Aventis
withdrawing it from markets where it was available and halting all other clinical studies.
Consequently, many other pharmaceutical companies have followed suit and disbanded their
CB1 antagonist-focused research efforts. Nevertheless, the wide-reaching therapeutic potential of
this treatment strategy necessitates further investigation. For example, the side effect profile of
rimonabant may be attributed in part to its inverse agonist activity, whereas a neutral, selective
CB1 antagonist might not produce such effects.
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Structure-activity relationship studies of rimonabant analogs have provided insight into
requisites of CB1 receptor recognition and antagonism. One surprising finding from such
investigations was that a number of compounds from a series of pyrazole-derived rimonabant
analogs with 3-substituent replacements (e.g., O-6629, O-6658) produced agonist-like effects in
the mouse tetrad, a model of cannabimimetic activity. Furthermore, these effects were not
reversed by rimonabant challenge, providing evidence that they are not mediated by CB1
receptors. The mechanism/s of action through which these compounds exert their behavioral
consequences is not understood. Therefore, the purpose of this study was to characterize the
pharmacological properties of these compounds using established behavioral techniques.
The first aim of this study was to replicate tetrad findings with O-6629 and O-6658.
Results from these experiments would be used to guide dosing regimens for later studies. It was
hypothesized that both O-6629 and O-6658 would produce dose-dependent tetrad activity, with
diminished potency relative to intravenous administration.
The second goal was to evaluate these and other pyrazole-derived rimonabant analogs in
THC drug discrimination, a preclinical model of the subjective/intoxicating properties of
marijuana. The high degree of pharmacological specificity offered by this model makes it an
ideal complement to tetrad findings. Selected compounds were evaluated in mice trained to
discriminate between the interoceptive stimuli elicited by THC or vehicle to determine whether
they engender or modify THC’s discriminative stimulus. It was hypothesized that 3-substituent
compounds that produced tetrad activity would not produce THC-like discriminative effects or
attenuate THC’s discriminative stimulus during challenge tests. Results from this series of
experiments were expected to reveal similarities or differences between the prototypic
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cannabinoid, THC, and rimonabant analogs that elicit a similar cannabimimetic profile, as
determined by the tetrad.
The final objective of this project was to train O-6629 as a discriminative stimulus and
subsequently investigate potential mechanisms of action. This goal was achieved through three
different approaches: First, rimonabant was evaluated for substitution for O-6629’s
discriminative stimulus. Additionally, O-6629’s discriminative stimulus was compared to O6658, a structurally similar 3-substituent rimonabant analog to determine whether these
compounds share similar discriminative stimuli, which would be indicative of shared mechanism
of action. The second approach investigated whether a spectrum of cannabinoid agonists share
discriminative stimulus effects with O-6629. Test compounds included the phytocannabinoid
THC, the potent synthetic agonist WIN 55,212-2, and the endogenous cannabinoid anandamide.
Finally, representative compounds from a number of drug classes with noted endocannabinoid
system interactions were evaluated to determine whether they engender O-6629-like
discriminative stimulus effects. Test compounds included cocaine, diazepam, morphine and
nicotine.
It was predicted that O-6629 would share discriminative stimulus effects with other 3substituent pyrazole analogs that display similar behavioral profiles in the tetrad, but would not
generalize to other cannabinoids. Given the extensive nature of endocannabinoid signaling with
other neurochemical systems, it was difficult to predict which, if any, of the proposed test
compounds would produce O-6629 discriminative stimulus effects. The potential for negative
data notwithstanding, this initial exploration into the pharmacological properties of O-6629 and
other 3-substituent pyrazole rimonabant analogs, at minimum, ruled out involvement from a
number of major receptor classes, including dopamine, µ-opioid, GABA and nicotinic
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acetylcholine systems. Further, should O-6629 serve as a discriminative stimulus in the absence
of other external manipulations (e.g., chronic cannabinoid treatment or taste aversion), this
would differentiate this analog from its parent compound.
In sum, despite an elevated risk of adverse psychiatric effects reported from clinical
investigations of rimonabant, the impetus to develop better pharmacotherapies for treatment of
obesity and various substance abuse disorders warrants further evaluation of CB1 receptor
antagonists. Such examinations have revealed a series of rimonabant analogs with 3-substituent
replacements that possess an uncharacteristic behavioral profile given their chemical derivation.
Therefore, this project sought to explore potential mechanisms of action for this class of
compounds utilizing drug discrimination, a behavioral assay that possesses an exceptionally high
degree of pharmacological specificity. This initial determination provided insight into the
behavioral activity of 3-substituent pyrazole analogs and excluded potential sites of their actions.

Methods
Experiment 1—Cannabimimetic effects of 3-substituent rimonabant analogs
Subjects
Forty-eight adult male, experimentally naïve C57BL/6J mice (20-25g) obtained from
Jackson Laboratories (Bar Harbor, ME) served as subjects. Mice were group housed (4-5/group)
in clear plastic cages with fitted tops and corncob bedding and had unlimited access to food
(Teklad chow; Harlan, Indianapolis, IN) and water in the home cage. Mice were housed in a light
◦

(12 hour light-dark cycle, lights on at 0600) and temperature (22-24 C) controlled vivarium. The
evening before testing, mice were randomly assigned and sorted into one of eight treatment
conditions (n=6 per treatment condition; 0, 1, 3, 10 mg/kg O-6629 or O-6658) and were
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transported to the laboratory where experimental test sessions would occur to allow them to
adjust to ambient room temperatures. The Guide for Care and Use of Laboratory Animals
(Institute of Laboratory Animal Resources, National Academy Press, 1996) was followed and the
Institutional Animal Care and Use Committee at Virginia Commonwealth University approved
the procedures described for all experiments described herein.
Drugs
O-6629 and O-6658 (Organix Inc., Woburn, MI) were dissolved in a vehicle consisting of
ethanol, Emulphor-620 (Rhone-Poulenc, Inc., Princeton, NJ), and saline at a ratio of 1:1:18.
Drugs were administered subcutaneously (s.c.) 60 min prior to the start of the experiments at a
volume of 10 ml/kg body weight.
Apparatus
Assessment of spontaneous activity in mice occurred in standard activity chambers
containing 8 photocell beams enclosed in sound and light attenuating cubicles (Med-Associates,
St. Albans, VT). Body temperature was measured by a telethermometer (Yellow Springs
Instrument Co., Yellow Springs, OH) and a thermistor probe inserted 25 mm into the rectum.
Antinociception was assessed using a standard tail flick apparatus. Catalepsy was evaluated
using a modified version of the ring immobility test (Pertwee, 1972), which was comprised of a
metal ring (5.5 cm in diameter) attached to a stand 16 cm above the surface where it was
situated.
Procedures
Each mouse was tested in all of the tetrad assays: locomotor activity, tail flick, rectal
temperature and ring immobility. Prior to drug administration, rectal temperature and baseline
tail flick latency were determined in the mice. The latter procedure involved placing the mouse’s

35

tail on an ambient heat source (i.e., bright light) and latency (in s) for tail removal served as the
dependent variable. Typical control latencies were 2-4 s. A 10 s maximal latency was used in
order to avoid damage to the mouse’s tail. After measurement of temperature and baseline tail
flick latency, mice were injected with vehicle or drug. One h later they were placed into
individual activity chambers for 10 min. Spontaneous activity was measured as the total number
of beam interruptions during the entire session, which was expressed as percent inhibition of the
control (vehicle) group’s activity. Immediately thereafter, mice were re-tested in the tail flick
procedure. Antinociception was expressed as the percent maximum possible effect (%MPE)
using a 10 s maximum test latency. %MPE was calculated using the following formula: [(test
latency-baseline latency)/(10-baseline latency)*100]. Rectal temperature was re-assessed next
and was expressed as the difference between pre- and post-injection rectal temperatures. Next,
mice were placed on the ring apparatus, and the amount of time the animals remained cataleptic
(i.e., motionless except for respiration; whisker movements were scored as movement) during a
5-min period was recorded. Percent immobility was expressed as [(time immobile/300)*100],
whereby 300 represented the total session time (300 s) and the dividend was multiplied by 100 to
create a percentage score.
Data analysis
Data for each assay and drug condition were analyzed using a one-way analysis of
variance (ANOVA). Significant differences between means were followed by a Dunnett’s posthoc test to identify differences relative to vehicle controls (p < 0.05).

Experiment 2—Discriminative stimulus effects of THC: evaluation of 3-substituent rimonabant
analogs
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Subjects
Sixteen adult male C57BL/6J wild type mice (20-25g) obtained from Jackson Laboratories
(Bar Harbor, ME) served as subjects. THC generalization data from a subset of these subjects were
previously reported by Wiley et al. (2011). Mice were housed individually in clear plastic cages with
fitted tops and corncob bedding. Mice were transported daily (Monday-Friday) from a light (12 hour
◦

light-dark cycle, lights on at 0600) and temperature (22-24 C) controlled vivarium to the laboratory
for experimental training and testing sessions. After one week of acclimation, subjects were food
restricted to 85-90% of their free feeding body weights to initiate the nose poke response and
weights were maintained by rationing daily food intake. Water was available ad libitum in the home
cages. When stable rates of responding were established on both nose poke apertures, subjects were
allowed to gradually gain weight as drug discrimination training progressed, provided the mouse
maintained 80% accuracy on the appropriate nose poke aperture.
Drugs
THC and rimonabant were obtained from the National Institute on Drug Abuse (Rockville,
MD) and dissolved in a mixture of 0.78% Tween-80 (Fischer Scientific, Pittsburgh, PA) and 99.22%
saline. O-4332, O-6629 and O-6658 (Organix Inc., Woburn, MI) were dissolved in a vehicle
consisting of ethanol, Emulphor-620 (Rhone-Poulenc, Inc., Princeton, NJ), and saline at a ratio of
1:1:18. All compounds were administered s.c. at a volume of 10 ml/kg body weight. THC and its
vehicle were administered 30 min pre-session, rimonabant was administered 40 min pre-session and
rimonabant analogs (i.e., O-4332, O-6629, O-6658) were administered 60 min pre-session.
Apparatus
Testing was conducted in eight standard computer-interfaced operant conditioning chambers
(Med Associates Inc., Georgia, VT) with two nose poke apertures in the left and right positions (8
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cm apart) on the front panel. Each aperture contained an infrared beam that was interrupted when a
mouse inserted their snout, which would count as one response. Centered between the apertures was
a recessed food receptacle connected to a food hopper that delivered reinforcement (14 mg
sweetened pellets; Bio-Serv, Frenchtown, NJ). The inner test chambers consisted of a 15 cm L X
11.5 cm D X 17.5 cm H area surrounded by an aluminum chassis box with a single Plexiglas side
door. Test chambers were housed in sound attenuated chambers and ventilation fans provided
masking noise. MED-PC software (Med Associates) controlled session parameters and recorded
data.
Training procedures
Nose poke training was initiated through an overnight session, during which mice were
placed in the operant chamber and trained to insert their snout into either nose poke aperture for a
sweetened food pellet on a fixed ratio one (FR1) schedule of reinforcement, in which a pellet was
delivered after every nose poke. Following this overnight session, the number of responses on both
the right and left apertures was calculated, and the preferred side (the side with the highest number
of responses) was determined. Mice were then trained to nose poke on the preferred aperture as the
value of the FR requirement was gradually increased over the next several sessions until subjects
responded readily under FR10 conditions. Once subjects maintained responding on the preferred
side, they were required to follow the same progression (i.e., FR1-FR10) on the non-preferred side.
Once stable rates of responding were achieved on both apertures, drug discrimination training
commenced.
Drug Discrimination Training
Mice were trained to discriminate 5.6 mg/kg THC vs. vehicle. On days when drug was
administered, only responses on the drug-associated aperture were reinforced.
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On days when

vehicle was administered, only responding on the vehicle-associated aperture was reinforced.
Responses on the incorrect aperture reset the ratio requirement on the correct aperture. The position
of the drug-associated aperture (left or right) was randomly assigned for all subjects. A double
alternation schedule (i.e., DDVVDDVV) was used during training and throughout the remainder of
the study.
Drug Discrimination Criteria
Successful acquisition of THC’s discriminative stimulus was demonstrated when subjects
met the following three criteria for 7 out of 8 consecutive sessions: (1) the first completed FR10 was
on the appropriate aperture, (2) 80% or greater of the total responding occurred on the appropriate
aperture and (3) response rate equaled or exceeded 0.17 responses per second (10 responses/min).
Control tests with vehicle and 5.6 mg/kg THC were administered and passed prior to generalization
testing with all new test drugs. During control and test sessions, responses on both apertures were
reinforced according to the FR10 schedule and the FR counter was reset if an animal interrupted
their responding on one aperture to respond on the opposite one. The three training criteria also had
to be met during the most recent training sessions with the training drug and vehicle immediately
prior to all test sessions.
Testing procedures
Generalization or substitution testing typically occurred on Tuesdays and Fridays with a
minimum of 2 days between tests, provided subjects passed training criteria during their most recent
drug and vehicle training sessions. After successful completion of vehicle and THC control tests, a
generalization dose effect curve was determined for THC (1-30 mg/kg) in all subjects. Next, doses
of rimonabant were tested in combination with the training dose to assess for CB1 mediation of
THC’s discriminative stimulus. Next, O-4332, O-6629 and O-6658 were tested alone to determine
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whether they occasioned THC-appropriate responding or altered THC’s discriminative stimulus. In
the event that a compound substituted for THC or altered THC’s discriminative stimulus, a challenge
with rimonabant was conducted. Finally, O-6629 and O-6658 were evaluated in combination with
the training dose of THC to determine whether they modified THC’s discriminative stimulus. New
control tests were performed between each new test drug with the training drug and vehicle to assess
THC discriminative stimulus control.
The rate suppressant effects of O-6629 precluded assessments of higher doses more relevant
to the dose of O-6629 trained as a discriminative stimulus in experiment 3 (5.6 mg/kg). Thus,
following a 1 week washout from their most recent test session (5 weeks from most recent test with
O-6658, a 3-substitutent pyrazole compound), mice were treated with 5.6 mg/kg O-6629 once daily
for consecutive 15 days to assess for tolerance to its rate suppressant effects. Tolerance to O-6629
was assessed during test sessions with 5.6 mg/kg O-6629 on days 1 and 12, whereby day 1 provided
a baseline measure of 5.6 mg/kg O-6629’s rate suppressant effects. Then, 5.6 mg/kg O-6629 was
tested in combination with 5.6 mg/kg THC on day 15. On training days, subjects were administered
5.6 mg/kg O-6629 immediately following their operant session. Control points with vehicle and
THC were conducted during this chronic dosing regimen on days 5 and 8, respectively, to ensure
subjects were accurately discriminating between the two conditions amidst post-session injections of
O-6629.
Data Analysis
The first FR (FFR) was collected for each test session and served as an index of accurate
discrimination during control tests. The number of responses on each aperture was recorded and
converted into percent drug lever responding (%DLR) by dividing the number of responses on the
drug aperture by total responses on both apertures and multiplying by 100. Responses per second
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(RPS) for each session were calculated. ED50 values (with 95% confidence intervals, C.I.) were
calculated for %DLR data using the least squares method of linear regression with the linear portion
of the dose effect curve (Bliss, 1967).

ED50 values were calculated for test drugs that fully

substituted for the training dose of THC (full substitution > 80% DLR; partial substitution was > 60
to < 80% DLR). A repeated-measures analysis of variance (ANOVA) comparing responses per
minute was performed for each drug (GraphPad Prism 5 for Mac OS X software; GraphPad
Software Inc., La Jolla, CA). Significant ANOVAs were followed by Dunnett’s post-hoc tests (p <
0.05 compared to vehicle). Subjects that failed to make ten or more responses during the course of
the test session had their %DLR data for that data point excluded from analysis.

Experiment 3—Discriminative stimulus effects of O-6629
Subjects
Thirty-one adult male C57BL/6J mice (Jackson Laboratories) served as subjects. All
other details same as experiment 2.
Drugs
Chlorpromazine hydrochloride and diazepam obtained from Sigma-Aldrich (St. Louis,
MO), and cocaine hydrochloride, morphine sulfate, and nicotine hydrogen tartrate salt were
obtained from the National Institute on Drug Abuse and dissolved in physiological saline. WIN
55,212-2 was obtained from Sigma-Aldrich and dissolved in a vehicle consisting of ethanol,
Emulphor-620, and saline at a ratio of 1:1:18. Anandamide was obtained from Organix Inc. and
dissolved in 0.78% Tween-80 and 99.22% saline. Cocaine and diazepam were administered i.p.
10 and 15 min pre-session, respectively. Morphine was administered s.c. 20 min pre-session.
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Anandamide, chlorpromazine and WIN 55,212-2 were administered s.c. 30 min pre-session.
Details for O-6629, O-6658, THC, and rimonabant are same as experiment 2.
Apparatus
Operant conditioning equipment described in experiment 2 was also used to conduct drug
discrimination sessions for experiment 3.
Training procedures
Nose poke training proceeded as described in experiment 2.
Drug Discrimination Training
Based upon test results obtained with O-6629 in experiments 1 and 2, a training dose of
5.6 mg/kg O-6629 was determined. Thus, mice were trained to discriminate 5.6 mg/kg O-6629
vs. vehicle. All other training details (e.g., acquisition criteria, data analysis) were identical to
those described in experiment 2.
Testing procedures
Once subjects met acquisition criteria and completed a dose effect curve with O-6629 (110 mg/kg), they were randomly assigned to one of three testing groups, each with a specific goal
(see Table 2). This three-group design was employed to facilitate data collection and maintain
identical drug history within subsets of the animals. The aim of the first group was to investigate
the structure-activity relationship among rimonabant analogs. Thus, O-6658 and rimonabant
were tested in relation to O-6629’s discriminative stimulus. The second group was tested with a
variety of cannabinoids, including the plant-derived partial agonist THC, the potent full efficacy
agonist WIN 55,212-2, and the endogenous cannabinoid anandamide. Finally, the third group
was tested with a variety of prototypical compounds from a number of major drug classes noted
for their interactions with the endocannabinoid system, including cocaine, diazepam, morphine,
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and nicotine. Additionally, chlorpromazine was tested based on its ability to produce activity in
all four assays of the tetrad within a limited dose range (Wiley & Martin, 2003). All test
compounds were evaluated alone to determine whether they elicited similar discriminative
stimulus effects as O-6629. If a compound substituted for O-6629, an appropriate challenge test
was conducted to further evaluate the mechanism/s of said effect. For example, if nicotine
attenuated O-6629’s discriminative stimulus, mecamylamine would be used to determine
whether that attenuation was due to nicotinic cholinergic activity or some other non-specific
effect (e.g., postsynaptic dopamine release). Table 2 provides a summary of test conditions for
these experiments.
Data Analysis
Drug

discrimination

data

were

analyzed
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as

described

in

experiment

2.

Table 2—Experiment 3 studies
Goals
Group 1
SAR of rimonabant and related
pyrazole compounds
Group 2

Evaluation of cannabinoids

Group 3

Evaluating other potential targets
responsible for O-6629’s
discriminative stimulus effects
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Generalization tests
Rimonabant
O-6658
THC
Anandamide
WIN 55,212-2
Cocaine (DA)
Morphine (µ-opioid)
Nicotine (ACh)

Results
Experiment 1—Cannabimimetic effects of 3-substituent rimonabant analogs
Pharmacological profile of O-6629 in the tetrad
Data from the evaluation of O-6629 in the tetrad battery are presented in Figure 2. O6629 significantly decreased spontaneous activity, F (3, 20) = 88.38, p < 0.05. Post-hoc analysis
revealed that activity at the 10 and 30 mg/kg doses was significantly decreased compared to
vehicle, p < 0.05. O-6629 produced significant antinociception in the tail flick assay, F (3, 20) =
3.26, p < 0.05. Post-hoc analysis revealed 30 mg/kg significantly increased %MPE compared to
vehicle, p < 0.05. O-6629 produced significant hypothermia, F (3, 20) = 78.16, p < 0.05. Posthoc analysis revealed body temperatures following 10 and 30 mg/kg doses were significantly
decreased compared to vehicle, p < 0.05. O-6629 produced significant catalepsy in the ring
immobility task, F (2, 15) = 17.06, p < 0.05. Post-hoc analysis revealed significant catalepsy
following 10 mg/kg administration, p < 0.05. All subjects treated with 30 mg/kg were unable to
remain situated on the ring, and after replacing each mouse back on the ring 5 times, assessment
of catalepsy ceased. Thus, no data are presented for this dose.
Pharmacological profile of O-6658 in the tetrad
Data from the evaluation of O-6658 in the tetrad battery are presented in Figure 3. O6658 significantly decreased spontaneous activity, F (3, 20) = 141.30, p < 0.05. Post-hoc
analysis revealed that activity at the 10 and 30 mg/kg doses was significantly decreased
compared to vehicle, p < 0.05. A significant antinociceptive effect of O-6658 was not observed,
F (3, 20) = 3.06, p > 0.05. O-6658 produced significant hypothermia, F (3, 20) = 164.00, p <
0.05. Post-hoc analysis revealed body temperatures following 10 and 30 mg/kg doses were
significantly decreased compared to vehicle, p < 0.05. O-6658 produced significant catalepsy in
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the ring immobility task, F (2, 15) = 7.71, p < 0.05. Post-hoc analysis revealed significant
catalepsy following 10 mg/kg administration. As was the case with O-6629, all subjects treated
with 30 mg/kg O-6658 were unable to remain situated on the ring following five attempts to
reinitiate assessment of catalepsy. Thus, no data are presented for this dose.

Experiment 2—Discriminative stimulus effects of THC: evaluation of 3-substituent rimonabant
analogs
THC’s discriminative stimulus: acquisition and generalization
Acquisition data for THC’s discriminative stimulus are presented in Figure 4. Thirteen
out of 16 subjects met acquisition criteria (correct FFR, > 80% condition-appropriate responding,
response rate > 0.17 responses/s) for 7 out of 8 consecutive sessions, consequently meeting
acquisition criteria in a mean of 29.50 sessions (SEM = 2.18). Range to acquisition was 14-49
sessions. Subjects that failed to meet acquisition criteria after 100 training sessions were
excluded from the study.
Results from generalization testing with THC in all subjects are presented in Figure 5.
Dose-dependent generalization with THC was observed, with a calculated ED50 of 2.37 mg/kg
(95% C.I. = 1.81-3.09). Partial substitution occurred at 3 mg/kg and full substitution was seen
following administration of 5.6, 10 and 30 mg/kg doses. Analysis of response rate data revealed
a significant effect of dose, F (7, 84) = 10.42, p < 0.05. Compared to vehicle, response rates were
significantly decreased at 10 and 30 mg/kg doses, p < 0.05.
Rimonabant challenge
Results from challenge tests with rimonabant against the training dose of THC (5.6
mg/kg) are presented in Figure 6. Rimonabant dose-dependently attenuated THC’s
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discriminative stimulus, with a calculated AD50 of 0.62 mg/kg (95% C.I. = 0.44 – 0.87).
Analysis of response rate data revealed a significant effect of dose, F (5, 25) = 3.46, p < 0.05.
Compared to vehicle, response rates were significantly decreased during control tests with the
highest dose of rimonabant tested (1 mg/kg), p < 0.05.
O-4332 generalization
Results from generalization testing with O-4332 are presented in Figure 7. O-4332 failed
to substitute for THC, eliciting a maximum 22.29% THC-appropriate responding at the 3 mg/kg
dose. Analysis of response rate data revealed a significant effect of dose, F (4, 32) = 16.02, p <
0.05. Compared to vehicle, response rates were significantly decreased by 10 and 30 mg/kg
doses, p < 0.05. Additionally, response rates for THC control tests were significantly higher than
vehicle, p < 0.05.
O-6629 generalization
Results from generalization testing with O-6629 are presented in Figure 8. O-6629 failed
to substitute for THC, eliciting a maximum 11.45% THC-appropriate responding at the 3 mg/kg
dose. Analysis of response rate data revealed a significant effect of dose, F (5, 15) = 5.39, p <
0.05. Compared to vehicle, response rates were significantly decreased by the 10 mg/kg dose, p
< 0.05. At this dose, all subjects made fewer than 10 responses during the test session; thus, no
generalization data are presented for this dose.
O-6629 challenge
Results from a challenge test with O-6629 against the training dose of THC are presented
in Figure 9. The 3 mg/kg dose of O-6629 resulted in a reduction of THC-appropriate responding
below full substitution criteria (71.82% DLR); however, inspection of data for individual animals
revealed that full substitution was observed in 3 out of 4 mice responding at this dose. Analysis
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of response rate data revealed a significant effect of dose, F (4, 28) = 14.91, p < 0.05. Compared
to vehicle, response rates were significantly decreased by 3.0 mg/kg O-6629 in combination with
the THC training dose, p < 0.05.
O-6658 generalization
Results from generalization testing with O-6658 are presented in Figure 10. O-6658
failed to substitute for THC, eliciting a maximum 3.95% THC-appropriate responding at the 1
mg/kg dose. O-6658 failed to significantly alter response rates, although a trend towards a
decrease in responding was observed, F (4, 20) = 2.57, p = 0.07.
O-6658 challenge
Results from a challenge test with O-6658 against the training dose of THC are presented
in Figure 11. No dose tested resulted in a reduction of THC-appropriate responding below full
substitution criteria. Analysis of response rate data revealed a significant effect of dose, F (4, 28)
= 5.90, p < 0.05. Compared to vehicle, response rates were significantly decreased by 1.0 and 3.0
mg/kg O-6658 in combination with the THC training dose, p < 0.05.
O-6629 tolerance
Results from the chronic dosing experiment assessing tolerance development to the rate
suppressant effects of 5.6 mg/kg O-6629 (dose trained as a discriminative stimulus in experiment
3) are presented in Figure 12. Analysis of response rate data revealed a significant effect of time
and treatment, F (4, 20) = 5.13, p < 0.05. Compared to vehicle, response rates were significantly
decreased following initial treatment with O-6629 (day 1), p < 0.05. Following 12 days of
chronic treatment, response rates did not differ significantly from vehicle, p > 0.05. However,
during a challenge test with 5.6 mg/kg O-6629 against the training dose of THC, response rates
were significantly decreased compared to vehicle, p < 0.05. Visual inspection of generalization
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data revealed a slight increase in %THC-appropriate responding on day 12 compared to day 1
(19.45% vs. 5.33%, respectively). Evaluation of individual data revealed that full substitution for
THC was observed in one subject, as opposed to a general increase in THC-appropriate
responding among all subjects. Thus, the chronic dosing regimen did not unmask a meaningful
alteration in O-6629’s ability to produce THC-like discriminative stimulus effects. Challenge test
data revealed a mean of 52.71% THC-appropriate responding. Evaluation of individual data in
subjects performing > 10 responses during the challenge test (n=3/6) revealed marked response
discrepancies among individual subjects (16.47%, 46.15%, 95.52%).

Experiment 3—Discriminative stimulus effects of O-6629
O-6629’s discriminative stimulus: acquisition and generalization
Acquisition data for O-6629’s discriminative stimulus are presented in Figure 13.
Twenty-seven out of 31 subjects met acquisition criteria for 7 out of 8 consecutive sessions,
consequently meeting acquisition criteria in a mean of 69.56 sessions (SEM = 6.13). Range to
acquisition was 26-133 sessions. Subjects not meeting acquisition criteria following 150 training
sessions were removed from the study. An additional subject passed away prior to completing
the O-6629 generalization curve.
Results from generalization testing with O-6629 in all subjects are presented in Figure 14.
Dose-dependent generalization with O-6629 was observed, with an ED50 of 2.15 mg/kg (95%
C.I. = 1.72-2.68). Full substitution was seen following administration of 5.6 and 10 mg/kg doses.
Analysis of response rate data revealed a significant effect of dose, F (5, 125) = 18.02, p < 0.05.
Compared to vehicle, response rates were significantly decreased at 5.6 and 10 mg/kg doses, p <
0.05.
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O-6658 generalization
Results from generalization testing with O-6658 are presented in Figure 15. O-6658 fully
substituted for O-6629, eliciting a maximum 91.86% O-6629-appropriate responding at the 10
mg/kg dose. Analysis of response rate data revealed a non-significant effect of dose, F (5, 15) =
1.75, p > 0.05.
Rimonabant generalization
Results from generalization testing with rimonabant are presented in Figure 16.
Rimonabant did not substitute for O-6629, eliciting a maximum 35.59% O-6629-appropriate
responding at the 0.1 mg/kg dose. Analysis of response rate data revealed a significant effect of
dose, F (6, 24) = 3.53, p < 0.05. However, post-hoc analysis did not reveal any significant
differences in response rate compared to vehicle.
THC generalization
Results from generalization testing with THC are presented in Figure 17. THC did not
substitute for O-6629, eliciting a maximum 51.60% O-6629-appropriate responding at the 1.0
mg/kg dose. Analysis of response rate data revealed a significant effect of dose, F (5, 25) = 3.05,
p < 0.05. Compared to vehicle, response rates were significantly decreased by the 10 mg/kg
dose, p < 0.05.
Anandamide generalization
Results from generalization testing with anandamide are presented in Figure 18.
Anandamide did not substitute for O-6629, eliciting a maximum 50.03% O-6629 appropriate
responding at the 10 mg/kg dose. Analysis of response rate data revealed a non-significant effect
of dose, F (5, 15) = 2.60, p > 0.05.
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WIN 55,212-2 generalization
Results from generalization testing with WIN 55,212-2 are presented in Figure 19. WIN
55,212-2 produced partial substitution for O-6629, eliciting a maximum 72.71% O-6629appropriate responding at the 1.7 mg/kg dose. Partial substitution was also observed following
administration of 3.0 mg/kg WIN 55,212-2. Analysis of response rate data revealed a significant
effect of dose, F (6, 18) = 6.97, p < 0.05. Compared to vehicle, response rates were significantly
decreased by the 3 mg/kg dose, p < 0.05.
Morphine generalization
Results from generalization testing with morphine are presented in Figure 20. Morphine
did not substitute for O-6629, eliciting a maximum 19.16% O-6629 appropriate responding at the
3 mg/kg dose. Analysis of response rate data revealed a significant effect of dose, F (4, 24) =
26.17, p < 0.05. Compared to vehicle, response rates were significantly decreased by 1, 3 and 10
mg/kg doses, p < 0.05. All subjects made fewer than 10 responses during the 10 mg/kg test
session; thus, no generalization data are presented for this dose. Additionally, response rates for
the O-6629 control test were significantly decreased relative to vehicle, p < 0.05.
Nicotine generalization
Results from generalization testing with nicotine are presented in Figure 21. Nicotine (1
mg/kg) produced partial substitution for O-6629, eliciting a maximum 76.88% O-6629
appropriate responding. Inspection of individual data revealed full substitution occurred in 3 out
of 4 subjects tested at this dose. A higher dose of nicotine (1.7 mg/kg) also generated partial
substitution for O-6629. Analysis of response rate data revealed a significant effect of dose, F (5,
15) = 7.49, p < 0.05. Compared to vehicle, response rates were significantly decreased by 1.7
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mg/kg nicotine, p < 0.05. Additionally, response rates for the O-6629 control test were
significantly decreased relative to vehicle, p < 0.05.
Five subjects were initially included in this dose effect determination, but one subject
died before completing the dose effect curve; thus, data from four subjects are presented. It
should be noted that this mouse responded almost exclusively on the vehicle-paired nose poke
aperture at doses tested (0.1-1 mg/kg), but that partial substitution still would have been observed
at the 1 mg/kg dose if their data were included.
Cocaine generalization
Results from generalization testing with cocaine are presented in Figure 22. Cocaine did
not substitute for O-6629, eliciting a maximum 49.69% O-6629-appropriate responding at the 1
mg/kg dose. Analysis of response rate data revealed a significant effect of dose, F (7, 28) =
10.95, p < 0.05. Compared to vehicle, response rates were significantly decreased by 10 and 30
mg/kg doses, p < 0.05. Additionally, response rates for the O-6629 control test were significantly
decreased relative to vehicle, p < 0.05.
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Figure 2. Pharmacological profile of O-6629 in the tetrad. Effects of O-6629 on spontaneous
activity (top left panel), body temperature (top right panel), catalepsy (bottom left panel) and tail
flick latency (bottom right panel). Values represent mean (+SEM) of 6 mice per treatment
condition. Asterisks (*) denote significant difference compared to vehicle, p < 0.05.
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Figure 3. Pharmacological profile of O-6658 in the tetrad. Effects of O-6658 on spontaneous
activity (top left panel), body temperature (top right panel), catalepsy (bottom left panel) and tail
flick latency (bottom right panel). All other details same as Figure 2.
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Figure 4. Acquisition of THC’s discriminative stimulus. Values represent percentage of subjects
meeting acquisition criteria across sessions (N = 13/16).
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Figure 5. THC generalization. Effects of THC on mean percentage THC-appropriate responding
(+SEM; top panel) and mean responses per second (+SEM; bottom panel) in mice trained to
discriminate 5.6 mg/kg THC from vehicle (N = 13). Values above VEH and THC represent
control test data collected prior to conducting the dose effect determination. The dashed line at
80% drug lever responding indicates full generalization to the training dose. For response rate
data, asterisks (*) denote significant differences compared to vehicle control, p < 0.05.
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Figure 6. Rimonabant challenge. Effects of rimonabant in combination with the THC training
dose on mean percentage THC-appropriate responding (+SEM; top panel) and mean responses
per second (+SEM; bottom panel) (N = 6). Values above 1.0 Rim + Veh represent control test
data with 1.0 mg/kg rimonabant in combination with vehicle. For percentage THC-appropriate
responding data, asterisks (*) denote significant differences compared to THC control, p < 0.05.
All other details same as Figure 5.
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Figure 7. O-4332 generalization. Effects of O-4332 on mean percentage THC-appropriate
responding (+SEM; top panel) and mean responses per second (+SEM; bottom panel) (N = 9).
All other details same as Figure 5.
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Figure 8. O-6629 generalization. Effects of O-6629 on mean percentage THC-appropriate
responding (+SEM; top panel) and mean responses per second (+SEM; bottom panel) (N = 4).
All other details same as Figure 5.
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Figure 9. O-6629 challenge. Effects of O-6629 in combination with the THC training dose on
mean percentage THC-appropriate responding (+SEM; top panel) and mean responses per
second (+SEM; bottom panel) (N = 8). All other details same as Figure 5.
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Figure 10. O-6658 generalization. Effects of O-6658 on mean percentage THC-appropriate
responding (+SEM; top panel) and mean responses per second (+SEM; bottom panel) (N = 6).
All other details same as Figure 5.
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Figure 11. O-6658 challenge. Effects of O-6658 in combination with the THC training dose on
mean percentage THC-appropriate responding (+SEM; top panel) and mean responses per
second (+SEM; bottom panel) (N = 6). All other details same as Figure 5.
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Figure 12. Evaluation of tolerance development to the rate suppressant effects of O-6629. Data
shown represent mean percentage THC-appropriate responding (+SEM; top panel) and mean
responses per second (+SEM; bottom panel) following administration of 5.6 mg/kg O-6629 on
days 1 and 12 and a challenge test against THC (N = 6). Points above VEH and THC refer to
control tests conducted with vehicle and the training dose of THC on days 5 and 8. All other
details same as Figure 5.
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Figure 13. Acquisition of O-6629’s discriminative stimulus. Values represent percentage of
subjects meeting acquisition criteria across sessions (N = 27/31).
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Figure 14. O-6629 generalization. Effects of O-6629 on mean percentage O-6629-appropriate
responding (+SEM; top panel) and mean responses per second (+SEM; bottom panel) in mice
trained to discriminate 5.6 mg/kg O-6629 from vehicle (N = 26). Values above VEH and O6629 represent control test data collected prior to conducting the dose effect determination. The
dashed line at 80% drug lever responding indicates full generalization to the training dose. For
response rate data, asterisks (*) denote significant differences compared to vehicle control, p <
0.05.
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Figure 15. O-6658 generalization. Effects of O-6658 on mean percentage O-6629-appropriate
responding (+SEM; top panel) and mean responses per second (+SEM; bottom panel) (N = 4).
All other details same as Figure 14.
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Figure 16. Rimonabant generalization. Effects of rimonabant on mean percentage O-6629appropriate responding (+SEM; top panel) and mean responses per second (+SEM; bottom
panel) (N = 5). All other details same as Figure 14.
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Figure 17. THC generalization. Effects of THC on mean percentage O-6629-appropriate
responding (+SEM; top panel) and mean responses per second (+SEM; bottom panel) (N = 6).
All other details same as Figure 14.
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Figure 18. Anandamide generalization. Effects of anandamide on mean percentage O-6629appropriate responding (+SEM; top panel) and mean responses per second (+SEM; bottom
panel) (N = 4). All other details same as Figure 14.
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Figure 19. WIN 55,212-2 generalization. Effects of anandamide on mean percentage O-6629appropriate responding (+SEM; top panel) and mean responses per second (+SEM; bottom
panel) (N = 4). All other details same as Figure 14.
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Figure 20. Morphine discrimination. Effects of morphine on mean percentage O-6629appropriate responding (+SEM; top panel) and mean responses per second (+SEM; bottom
panel) (N = 7). All other details same as Figure 14.
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Figure 21. Nicotine generalization. Effects of nicotine on mean percentage O-6629-appropriate
responding (+SEM; top panel) and mean responses per second (+SEM; bottom panel) (N = 4).
All other details same as Figure 14.
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Figure 22. Cocaine generalization. Effects of cocaine on mean percentage O-6629-appropriate
responding (+SEM; top panel) and mean responses per second (+SEM; bottom panel) (N = 5).
All other details same as Figure 14.
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Discussion
The present study evaluated the 3-substitutent rimonabant analogs O-6629 and O-6658 in
two behavioral assays, the tetrad and drug discrimination. Activity in all four tests of the tetrad
battery (Experiment 1) across a similar dose range is often predictive of cannabimimetic activity,
whereas

THC

drug

discrimination

(Experiment

2)

serves

as

a

model

for

the

psychoactive/intoxicating properties produced by marijuana in human users. In addition to
comparing a discriminative stimulus of a drug with known mechanism of action to other drugs,
the robust pharmacological specificity afforded by drug discrimination also permits training of
drugs with unknown mechanism of action. In this case, O-6629 was trained as a discriminative
stimulus (Experiment 3) and evaluated against drugs from several pharmacologically distinct
classes with well-established mechanisms of action. The results of the present study indicate that
O-6629 and O-6658 do not exert their effects through established cannabinoid mechanisms.
When evaluated in the tetrad battery, O-6629 produced significant decreases in
spontaneous activity and body temperature, as well as significant antinociception and catalepsy.
Like O-6629, O-6658 significantly decreased spontaneous activity and body temperature and
produced catalepsy; however, a significant antinociceptive effect was not observed with O-6658.
Although O-6629, and to a lesser extent O-6658, produced behavioral activity in the tetrad, these
compounds differed from THC in regards to the maximal effects elicited by the latter. For
example, THC reliably produces 4-6° C decreases in body temperature (Compton, Johnson,
Melvin, & Martin, 1992; Wiley & Martin, 2003), which contrasts sharply with the 11° C
decrease observed following O-6629 or O-6658 administration. In addition, catalepsy in THC
treated mice typically ranges between 50-60% time immobile (Compton et al., 1992; Wiley &
Martin, 2003). Maximal catalepsy produced by O-6629 and O-6658 was similar (28.28% and
32.11%, respectively). When tested with the high dose (30 mg/kg) of either compound, severe
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loss of motor function was observed as demonstrated by tests of spontaneous activity test, and
during the ring test, as all subjects were unable to remain positioned on the ring despite
numerous trials of placing each mouse on the apparatus. A seizure was observed in one subject
treated with 30 mg/kg O-6658. Administration of 3 mg/kg of either analog did not produce any
behavioral activity, whereas significant decreases in spontaneous activity and body temperature
were present with 10 mg/kg. Thus, 3 mg/kg doses of either analog would not be predicted to
decrease operant response rates in drug discrimination as a result of motoric deficits.
Interestingly, the indole-derived potent CB1 agonist WIN 55,212-2 produces a behavioral
profile rather similar to those elicited by the 3-substituent rimonabant analogs evaluated in this
study, including 11° C decreases in body temperature, near complete suppression of spontaneous
activity, and approximately 30% time immobile during assessment of catalepsy (Compton, Gold,
Ward, Balster, & Martin, 1992). Despite these similarities, the 3-substituent rimonabant analogs
evaluated here differed from WIN 55,212-2 and other cannabinoid agents in terms of their ability
to produce antinociception. Whereas THC, WIN 55,212-2 and a variety of other cannabinoid
agonists produce a full antinociceptive effect (e.g., 10 s latency in tail flick; 100% MPE), O-6629
and O-6658 produced 42% and 23% MPE, respectively. One possible explanation for the
diminished antinociceptive effect seen with the rimonabant analogs is pharmacokinetic factors,
as intravenous administration of these compounds produced a maximal antinociceptive effect (JL
Wiley, unpublished data). Additionally, the overwhelming majority of tetrad determinations have
utilized intravenous or intraperitoneal route of administration, whereas the subcutaneous
injections were performed for these studies. Another key consideration is that C57BL/6 mice
were used in the present study, whereas ICR mice have typically served as subjects in the tetrad
in this laboratory.
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Several other drug classes have been shown to produce cannabimimetic activity in the
tetrad through a non-CB1 mechanism. As mentioned previously, some antipsychotic drugs, such
as chlorpromazine displayed a cannabimimetic profile in the tetrad that was not reversed by
rimonabant (Wiley & Martin, 2003). The endogenous cannabinoid anandamide also produced
activity in the tetrad, but was not reversed by rimonabant (Adams, Compton, & Martin, 1998).
Further, tetrad effects were present following anandamide administration in CB1 knockout mice
(Di Marzo et al., 2000b). A series of investigations on arvanil, a hybrid cannabinoid and
vanilloid derived from the chemical structures of anandamide and capsaicin (Melck et al., 1999)
provided further support for the possible existence of novel receptors that mediate cannabinoid
activity. When evaluated in the tetrad, arvanil produced tetrad activity similar to anandamide
(i.e., THC-like responses for spontaneous activity, antinociception and catalepsy; 3°C decreases
in body temperature) that was not reversed by rimonabant (Di Marzo et al., 2000a). Arvanil was
also more potent than capsaicin in generating antinociception, but arvanil’s antinociceptive
properties were not blocked by the TRPV1 antagonist capsazepine, whereas capsaicin-induced
antinociception was reversed (Di Marzo et al., 2000a).
In sum, the tetrad has served as a tremendously valuable screen for assessing cannabinoid
activity in vivo. A drug is likely to possess cannabinoid activity when it: 1) produces activity in
all four tests to a comparable magnitude as cannabinoid agonists (i.e., approximately 90%
suppression of spontaneous activity, 100% MPE, Δ -6° C, 60% time immobile) and 2) does so
within a similar dose range between all four tests. The 3-substitutent rimonabant analogs
evaluated in this study were active in the tetrad, but to a different degree than the prototypic
cannabinoid THC. Combined with earlier findings demonstrating rimonabant’s inability to
reverse these effects, as well as their presence in CB1 knockout mice, it can be concluded that
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the activity produced by these 3-substituent rimonabant analogs is mediated through a non-CB1
mechanism. Interestingly, these analogs actually produced a behavioral profile more similar to
WIN 55,212-2 than THC, suggesting that these analogs might be acting through a novel
cannabinoid mechanism. This possibility will be discussed later.
THC (5.6 mg/kg) readily served as a discriminative stimulus in mice, with subjects meeting
acquisition criteria in a mean of 29.50 sessions. Dose-dependent generalization to THC’s
discriminative stimulus was observed as is typical for studies of this nature, with partial
substitution occurring at the 3 mg/kg dose. None of the 3-substituent rimonabant analogs
evaluated produced full or partial substitution for THC, providing evidence that these analogs do
not produce THC-like psychoactivity.
Although THC discrimination has been established in mice only recently, the
pharmacological specificity of this model in the species has been demonstrated by findings from
our laboratory and others. The structurally dissimilar synthetic agonists CP55,940 and WIN
55,212-2 both substitute for THC (McMahon et al., 2008), as does the endocannabinoid
anandamide in the presence of a FAAH inhibitor (Vann et al., 2009a). On the contrary, noncannabinoids (e.g., cocaine, ethanol and ketamine) do not elicit THC-like responding (McMahon
et al., 2008). THC discrimination in mice has also been used in combination with other in vivo
and in vitro techniques as a mechanistic tool for evaluating a putative neutral CB1 receptor
antagonist (Wiley et al., 2011) and salvinorin A, the psychoactive constituent of Salvia
divinorum (Walentiny et al., 2010).
In the present study, THC’s discriminative stimulus was dose-dependently attenuated by
rimonabant, in accordance with a number of reports demonstrating CB1 receptor mediation of
THC’s discriminative stimulus in mice (McMahon et al., 2008; Vann et al., 2009a) and other
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species (Wiley et al., 1995b; Mansbach et al., 1996). Results from challenge tests with O-6629
and O-6658 revealed that these compounds failed to markedly attenuate THC’s discriminative
stimulus. Although a challenge with 3 mg/kg O-6629 decreased THC-appropriate responding
below full substitution criteria (i.e., < 80% THC-appropriate responding), it should be noted that
full substitution was observed in 3 out of 4 mice responding during that test session. Response
rates were severely suppressed (i.e., < 10 total responses) for the remaining 4 mice and their
generalization data were subsequently excluded from analysis. Thus, despite their chemical
derivation and CB1 receptor affinity, it is unlikely that O-6629 and O-6658 are acting as
functional antagonists of CB1 receptors.
Although these compounds failed to modify the training dose of THC, it is possible that
these 3-substituent rimonabant analogs might have produced shifts in the THC dose effect curve.
A number of agonists from distinct pharmacological classes (e.g., µ-opioid, acetylcholine,
dopamine) have been shown to shift the THC dose effect curve leftward through a noncannabinergic mechanism in rats (Solinas & Goldberg, 2005a; Solinas et al., 2007a; Solinas et
al., 2010). Interestingly, these drugs did not produce substitution when given alone, nor did their
respective antagonists attenuate the discriminative stimulus of the THC training dose. These
findings, and others (e.g., partial substitution for THC produced by diazepam Wiley & Martin,
1999) clearly demonstrate that a number of neurochemical systems can influence the
discriminative stimulus effects of THC and may be attributable to co-localization of CB1
receptors with other neurotransmitter systems.
Due to limited drug supply, O-4332 was only evaluated for generalization to THC’s
discriminative stimulus. Similar to the other 3-substituent analogs, O-4332 did not substitute for
THC. Although a challenge test was not conducted with O-4332, it is unlikely that O-4332
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would have modified THC’s discriminative stimulus. The weak CB1 receptor affinity (relative to
the other analogs tested; Table 1), and lack of observed effect with other 3-substituent
rimonabant analogs on THC’s discriminative stimulus support this hypothesis.
Given the lack of apparent behavioral activity of 3 mg/kg O-6629 in the tetrad compared to
the robust behavioral effects seen with 10 mg/kg, 5.6 mg/kg O-6629 was chosen as the initial
target dose to train as a discriminative stimulus. Results obtained in THC-trained mice
demonstrated development of tolerance to the rate suppressant effects of 5.6 mg/kg O-6629
following 12 days of once daily chronic treatment, lending further evidence that this dose would
be suitable for training as a discriminative stimulus.
Attempts to train 5.6 mg/kg O-6629 as a discriminative stimulus were successful, with
subjects acquiring the discrimination in a mean of 69.56 sessions. Acquisition of O-6629’s
discriminative stimulus took appreciably longer than THC. Several possible factors contributed
to this, including a longer time to develop tolerance to the rate suppressant effects of O-6629
relative to THC. Indeed, response rates during O-6629 control tests were often, but not always,
lower than vehicle control rates. Additionally, experimenter history could account for some of
the discrepancy in latency to meet acquisition criteria, as our laboratory has had extensive
experience training THC as a discriminative stimulus, but O-6629 has never been trained in this
procedure. Nonetheless, the ability of O-6629 to serve as a traditional discriminative stimulus
(i.e., drug vs. non-drug discrimination without other manipulations) differentiates it from
rimonabant. The fact that systemically administered O-6629 trained as a discriminative stimulus
also provides strong behavioral evidence that O-6629 penetrates the blood brain barrier, as
peripherally restricted drugs fail to serve as discriminative stimuli.
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Although the present study did not evaluate whether other doses of O-6629 would serve as
a discriminative stimulus, it is likely, albeit speculative, that the rate suppressant effects of O6629 would limit training efforts of a higher dose as a discriminative stimulus. Rate suppression
is frequently observed during initial dosing in drug discrimination procedures and typically
diminishes over the course of training as a result of frequent (but not chronic) exposure to the
same drug dose. Other methodological manipulations (e.g., initial chronic exposure as opposed
to double alternation) might have facilitated acquisition of O-6629’s discriminative stimulus.
Also unclear is whether lower doses of O-6629 would serve as a discriminative stimulus.
While 3 mg/kg O-6629 did not produce any activity in the tetrad, this dose did disrupt operant
responding in mice discriminating THC. Training dose has been shown to be a critical
determinant of a drug’s ability to function as a discriminative stimulus and different training
doses can result in different substitution patterns with test compounds (Picker et al., 1993; Jarbe
et al., 1998; Porter, Varvel, Vann, Philibin, & Wise, 2000; Jarbe et al., 2000). Thus, the
pharmacological specificity of a drug’s discriminative stimulus has the potential to be modified
as a function of training dose.
O-6658 fully substituted for O-6629, providing further evidence that these two analogs
share a common mechanism of action. Also, no significant rate suppression was observed with
the dose of O-6658 (10 mg/kg) that substituted for O-6629. The parent compound rimonabant
(0.1-10 mg/kg) did not engender meaningful O-6629-like responding, nor did it perturb operant
response rates. This latter finding is particularly interesting, given rimonabant’s well-established
ability to diminish food intake. In the current study, 1 mg/kg rimonabant significantly decreased
response rates when given alone, but not in combination with THC (experiment 2). This
discrepancy might be indicative of some cross-tolerance between the appetite disrupting effects
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of rimonabant and O-6629, but other interpretations are possible. For instance, vehicle response
rates were lower in the THC-trained mice during rimonabant tests compared to O-6629 mice
(0.29 vs. 0.49 responses/s). Also unclear is to the influence O-6629 or similar analogs have on
feeding behavior, as will be discussed in further detail later.
Significant rate suppression was observed during O-6629 control tests for the morphine
and cocaine dose effect determinations, suggesting only a partial degree of tolerance
development to the rate suppressant effects of 5.6 mg/kg O-6629 over the course of the
experiment. In the present study, 3 mg/kg O-6629 severely suppressed response rates (< 10 total
responses during test session) in 3 out of 4 subjects in the THC discrimination experiment.
However, the mean response rate at this dose was not significantly different from vehicle, likely
attributable to small sample size. It is currently unknown whether O-6629 or similar analogs
would decrease food intake at doses that do not suppress locomotor activity, but these
preliminary findings and rimonabant’s known effects on food intake suggest this could be a
possibility.
Another possibility is that these analogs might decrease motivation to respond for a food
reinforcer. One approach to investigate this would be to evaluate the effects of these analogs in
animals responding under a food-reinforced progressive ratio schedule, whereby behavioral
requirements for food reinforcement increase systematically (e.g., FR1, FR2, FR4, FR8, etc.)
over the course of an experimental session (Hodos, 1961). Drug treatment that results in a
subject extinguishing responding at a final fixed ratio schedule (referred to as breakpoint) lower
than vehicle would be indicative of a decrease in the subject’s motivation to respond for food
reinforcement. Preclinical investigations of rimonabant’s effects on food-reinforced PR
breakpoints have yielded mixed findings (Solinas & Goldberg, 2005b; Maccioni, Pes, Carai,

81

Gessa, & Colombo, 2008; Ward & Walker, 2009), which may be explained in part by
methodological variations between studies. Co-evaluations of O-6629 and other analogs in
measures of non-contingent feeding behavior, fixed ratio operant responding, progressive ratio
operant responding and locomotor activity would serve as an initial attempt to dissociate
between locomotor versus potential appetitive and/or motivational alterations these compounds
may produce.
THC failed to produce O-6629-like discriminative stimulus effects, even at doses that
suppressed operant response rates. The greatest degree of O-6629-like responding occurred at the
lowest dose tested (1 mg/kg). Full substitution was observed in half the subjects receiving this
dose, but this effect did not persist during tests with higher doses. In the event that O-6629’s
discriminative stimulus was mediated totally or in part by cannabinergic activity, one would
expect increases in O-6629-appropriate responding at higher THC doses. Taken together with
results obtained in mice discriminating THC, there is no evidence to suggest that O-6629
produces cannabis-like intoxication.
Similarly, anandamide did not substitute for O-6629 but failed to decrease rates at doses
tested (1-30 mg/kg). These results are not surprising, provided that anandamide was given in the
absence of a metabolic inhibitor (e.g., URB597, PF-3845). Like THC, a moderate amount of O6629-appropriate responding (~50%) was observed at one dose tested (10 mg/kg), whereby
substitution was observed in half of the subjects tested. Any potential trend towards substitution
was not observed during tests with lower or higher doses.
In contrast to these results obtained with centrally active cannabinoids, several doses of
WIN 55,212-2 (1.7 and 3.0 mg/kg) produced partial substitution for O-6629’s discriminative
stimulus. Although the precise mechanism of action for O-6629 and other related analogs has not
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yet been determined, these compounds may be acting through an, as of yet, undetermined
cannabinoid mechanism. Indeed, mounting behavioral and neurochemical evidence from tests
with anandamide and WIN 55,212-2 suggest the possible existence of [a] novel cannabinoid
receptor/s. Anandamide was first shown to produce activity in the tetrad similar to THC, yet
these effects were not reversed by rimonabant (Adams et al., 1998). An evaluation of
cannabinoid effects on food-maintained operant responding in CB1 wild-type and knockout mice
revealed that THC dose-dependently decreased operant responding in wild-type mice, but had no
influence on response rate in knockout mice (Baskfield, Martin, & Wiley, 2004). However,
methanandamide, an analog of anandamide with increased metabolic stability, decreased
response rates to a similar degree in both genotypes (Baskfield et al., 2004). Somewhat
surprisingly, this effect did not carry over during tests with O-1812, a methanandamide analog
that produces THC-like discriminative stimulus effects in rats (Wiley et al., 2004) and mice
(unpublished data, JL Wiley et al.).
In addition to this behavioral evidence, both anandamide and WIN 55,212-2, but not THC,
have been reported to stimulate [35S]GTPγS binding in CB1 knockout mice (Breivogel, Griffin,
Di Marzo, & Martin, 2001). Analysis of specific brain regions in these mice revealed significant
[35S]GTPγS binding increases in brain stem, cortex, hippocampus, diencephalon, midbrain, as
well as in the spinal cord (Breivogel et al., 2001). Interestingly, [35S]GTPγS binding was not
enhanced in basal ganglia (composed of striatum and globus pallidus) or cerebellum tissue,
providing evidence that localization of this putative novel cannabinoid receptor might not
completely overlap with CB1 receptor distribution.
A recent study by Nguyen et al. (2010) examined agonist stimulated [35S]GTPγS binding
utilizing a novel 3D reconstruction of whole mouse brain. Results obtained in brains from CB1
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knockout mice treated with WIN 55,212-2 largely echoed findings from Breivogel and
colleagues (2001), including enhanced [35S]GTPγS binding in brain stem, cortex, and
hippocampus, with no significant difference noted in the basal ganglia (Nguyen et al., 2010). In
contrast, increased binding was noticed in the cerebellum, potentially confined within the
molecular layer (Nguyen et al., 2010). WIN 55,212-2 has also been shown to decrease the
amplitude of excitatory postsynaptic currents in CB1 -/- and +/+ mice in the hippocampus,
whereas inhibitory postsynaptic currents were only altered in CB1 +/+ mice (Hajos, Ledent, &
Freund, 2001). These findings suggested the WIN 55,212-2 influences glutamatergic function
through a non-CB1 mechanism.
As noted previously, the 3-substituent rimonabant analogs evaluated in this study produced
tetrad activity in a similar manner as WIN 55,212-2 and O-6629’s discriminative stimulus was
partially generalized by WIN 55,212-2. The marked differences in the efficacy of these analogs
and WIN 55,212-2 to further decrease body temperature and produce less catalepsy relative to
THC might be suggestive of a shared non-CB1 mediated mechanism of action for these
compounds. One methodological approach to test this hypothesis would be to determine whether
cross-tolerance develops between WIN 55,212-2 and O-6629 in the tetrad following chronic
administration of either drug.
While some similarities exist between the pharmacological profiles of WIN 55,212-2 and
the 3-substituent rimonabant analogs evaluated in the present study, notable differences exist.
WIN 55,212-2 has high affinity and efficacy at CB1 receptors, whereas O-6629 and O-6658 have
moderate affinity for the receptor with no evidence of efficacy. Additionally, crossgeneralization is observed between the discriminative stimulus effects of WIN 55,212-2 and
THC (Wiley, 1999). In contrast, the rimonabant analogs did not produce THC-like
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discriminative stimulus effects, nor did O-6629’s discriminative stimulus generalize to THC.
Nevertheless, the similar profiles of WIN 55,212-2 and the 3-substituent rimonabant analogs in
the tetrad and partial substitution observed with WIN 55,212-2 in mice discriminating O-6629
combined with a number of non CB1-mediated effects observed with these compounds supports
future testing to compare their pharmacological properties.
The fact that certain alterations in the 3-substituent of rimonabant conferred drastic
functional changes in the pharmacodynamic and behavioral properties relative to the parent
compound is quite interesting. Based upon findings obtained upon evaluation of O-6629 and O6658 in the tetrad and drug discrimination, several avenues towards further elucidating the
pharmacological properties of this class of 3-substituent rimonabant analogs are evident. First,
generalization tests with other similar 3-substituent rimonabant analogs would help determine
the pharmacological specificity of O-6629’s discriminative stimulus and possible structural
requisites for eliciting O-6629-like discriminative stimulus effects. O-6629 and O-6658 are
nearly identical structurally, differentiated only by a bromine or azide group, respectively. It
would be interesting to see if 3-substituent analogs with carbon chain substituents that produce
cannabimimetic activity (Wiley et al., 2001) would engender O-6629’s discriminative stimulus.
The similarities in magnitude of observed tetrad effects produced between these analogs
and those reported for WIN 55,212-2 and WIN 55,212-2’s partial substitution for O-6629 are
also intriguing. Several lines of evidence strongly suggest that WIN 55,212-2 has activity at one
or more novel cannabinoid receptors. One caveat to evaluating WIN 55,212-2 in O-6629 trained
mice is that the high efficacy of WIN 55,212-2 at CB1 receptors might potentially mask the
ability for the animal to detect non-CB1 mediated discriminative stimulus effects. To counteract
this, WIN 55,212-2 could be given in the presence of rimonabant to block its activity at CB1
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receptors. Another strategy to evaluate potential shared mechanism of action of O-6629 and WIN
55,212-2 would be to see if cross-tolerance develops to the effects of these compounds in the
tetrad following chronic treatment with either.
Interestingly, 1 mg/kg nicotine also produced partial substitution (61.60 %DLR) for O6629’s discriminative stimulus. Full substitution for O-6629’s discriminative stimulus was
observed in 3 out of 5 subjects tested with this dose, whereas vehicle-appropriate responding was
predominantly observed in the remaining two subjects. These differences in substitution patterns
between subjects might be attributable to individual differences in stimulus control or sensitivity
to a potential nicotinic acetylcholine component of O-6629’s discriminative stimulus. Increasing
the sample size for this generalization curve would be a prudent first step to help reduce the large
margin of error present in the current sample. In the event that partial or even full substitution
persisted in a larger number of subjects, challenge tests with the nicotinic antagonist
mecamylamine against nicotine would provide insight as to whether nicotine’s ability to
engender O-6629-appropriate responding was due to nicotinic acetylcholine receptor activity.
Similarly, a mecamylamine challenge against O-6629 would also provide evidence as to whether
O-6629’s discriminative stimulus was mediated through a nicotinic acetylcholine mechanism.
A number of findings have demonstrated functional interactions between nicotinic
acetylcholine and cannabinergic systems. Rimonabant reduced nicotine self-administration
behavior (Cohen, Perrault, Voltz, Steinberg, & Soubrie, 2002) and blocked cue-induced
reinstatement of nicotine self-administration (Cohen, Perrault, Griebel, & Soubrie, 2005; De
Vries, de Vries, Janssen, & Schoffelmeer, 2005), and reverse expression of nicotine conditioned
place preference (Le Foll & Goldberg, 2004). In rats trained to discriminate THC from vehicle,
nicotine and the muscarinic agonist pilocarpine both shifted the THC dose effect curve leftward,
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but failed to substitute for THC when given alone (Solinas et al., 2007a). These shifts were
reversed by nicotinic or muscarinic antagonists, respectively, but rimonabant only blocked the
nicotine-induced shift. (Solinas et al., 2007a). Additionally, following pretreatment with the
FAAH inhibitor URB597, nicotine produced high levels of THC-appropriate responding, which
was partially reversed by rimonabant (Solinas et al., 2007a). Taken together with results of the
present study, it is possible that nicotinic acetylcholine receptors might engage in crosstalk with
both established and novel cannabinoid receptors. However, further investigation towards this
end is necessary to test this hypothesis.
The prototypical opioid morphine failed to substitute for O-6629, but significant rate
suppression was observed across all doses tested (1-10 mg/kg). Morphine and other opioids have
frequently been evaluated in drug discrimination. An abundance of evidence points to µ-opioid
mediation of morphine’s discriminative stimulus, including cross-generalization between opiates
such as fentanyl and morphine, lack of substitution with δ or κ-selective agonists, and blockade
of discriminative stimulus effects with µ-opioid antagonists (for review, see Dykstra, Preston, &
Bigelow, 1997). Thus, it is unlikely that O-6629 and other similar analogs produce their effects
through µ-opioid receptors. This conclusion is not too surprising given the relative lack of
antinociceptive efficacy of systemically administered O-6629 and O-6658 in the tetrad, even at
doses that severely decreased spontaneous activity. It should be noted that maximal
antinociception in the tail flick assay has been observed following intravenous administration
with both of these analogs in ICR mice (JL Wiley, unpublished data).
Cocaine also did not engender O-6629’s discriminative stimulus, with significant rate
suppression observed with 10 and 30 mg/kg doses. Cocaine has been shown to exert
discriminative control in laboratory animals through mesocorticolimbic dopaminergic activity
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(Callahan, De La Garza, & Cunningham, 1997). While some degree of O-6629-appropriate
responding was seen during generalization tests with cocaine, inspection of individual data
revealed full substitution for O-6629 in one subject across all cocaine doses tested, with vehiclelike responding occurring in the majority of other subjects.
In sum, the results of the present study substantiated initial findings from our laboratory
that suggested 3-substituent rimonabant analogs that produce cannabimimetic activity in the
tetrad exert their behavioral effects through a non-CB1 mechanism. Analogs that retained a
cyclic structure in the 3-substituent were highly unlikely to produce cannabimimetic activity,
whereas certain carbon chain substitutions conferred agonist-like effects in the tetrad (JL Wiley
unpublished data; present study). Notably, these effects were also present in CB1 receptor
knockout mice and were not reversed by rimonabant pretreatment in wild-type mice (JL Wiley,
unpublished data). O-6629 and O-6658, two novel 3-substituent rimonabant analogs evaluated in
the present study, produced activity in the tetrad, but with noticeable differences in observed
effect relative to THC. These compounds did not elicit THC-like discriminative stimulus effects
in mice, nor did they modify the discriminative stimulus of the THC training dose. Finally, in
mice discriminating O-6629 from vehicle, O-6658 dose-dependently substituted for the training
drug. Additionally, partial substitution was observed with both WIN 55,212-2 and nicotine,
whereas a number of other cannabinoid and non-cannabinoid test compounds failed to substitute
for O-6629. Despite their affinity for CB1 receptors, the effects produced by these rimonabant
analogs are almost certainly not attributable to CB1 receptor activity, nor do these compounds
antagonize the classic pharmacological and discriminative stimulus effects of the prototypical
cannabinoid THC.
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Other worthwhile endeavors to pursue in mice trained to discriminate O-6629 would be to
test anandamide in the presence of a FAAH inhibitor. Whether or not anandamide would
substitute for O-6629 under more metabolically stable conditions is a matter of speculation, but
anandamide has also been shown to produce cannabimimetic activity in the tetrad and other
behavioral effects through a non-CB1, non-TRPV1 mechanism. The lack of any behavioral
activity of anandamide (i.e., substitution or rate suppression) provides further justification for
this proposed test. Generalization tests with chlorpromazine, a false positive in the tetrad, and
diazepam, which produces partial substitution for THC’s discriminative stimulus would also be
appropriate choices.
One primary rationale for evaluating rimonabant analogs is to identify compounds that
produce therapeutically beneficial effects with a lower incidence of side effects. Certainly,
rimonabant’s preclinical and clinical effects on appetite and its history as a marketed anti-obesity
medication would suggest that some analogs might produce appetitive effects. Some preliminary
evidence provided in this study demonstrated that a dose of O-6629 that did not alter locomotor
activity markedly suppressed food-maintained operant response rates in a large percentage of
mice tested in the THC discrimination experiment. However, limited inferences regarding these
two findings can be made, given the increased demand on motor coordination to perform a
specific operant response versus gross locomotor activity, coupled with the cognitive demand
required of subjects in a drug discrimination task. Moreover, differences in motivational
components for tests of spontaneous activity (no food reinforcement; free-feeding subjects) and
drug discrimination (palatable food reinforcement; food-restricted subjects) also cloud
interpretation. As mentioned previously, a series of studies investigating a range of doses of O6629 and/or related analogs effects on locomotor activity and food-reinforced operant behavior
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under several different schedules of reinforcement (e.g., fixed ratio and progressive ratio) would
help delineate the role of the known motor suppressant effects produced by these analogs from
potential appetitive and/or motivational influences.
Insofar as drug discrimination is one preclinical measure of a drug’s abuse liability,
generalization testing with morphine and cocaine would suggest that 3-substituent rimonabant
analogs with similar pharmacological properties as O-6629 do not produce intoxicating effects
similar to morphine or cocaine. Further testing with nicotine is necessary before determining the
degree to which nicotine and O-6629 share discriminative stimulus effects before any clear
inferences can be drawn in that regard.
Some of the most convincing neurochemical support for the existence of novel cannabinoid
receptors is that WIN 55,212-2 stimulates [35S]GTPγS binding in CB1 -/- mice. Thus, it would be
interesting to see if O-6629 or other rimonabant analogs would be able to stimulate binding in
CB1 -/- mice as well. In the event that enhanced binding was observed following drug treatment,
regional distribution of receptor activation could provide insight into other physiological
processes these compounds might influence.
In conclusion, the findings of the present study provide substantial behavioral evidence
that the pharmacological properties of 3-substituent rimonabant analogs are not attributable to
their affinity for CB1 receptors. In fact, based on the present findings demonstrating similarities
between the tetrad profile of these analogs and WIN 55,212-2 and the observed partial
substitution with the latter for O-6629, it is possible that these compounds are producing their
effects, at least in part, through a novel cannabinergic mechanism. Further work is needed to
substantiate this claim, but this possibility is certainly an intriguing one.
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